IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Public Comment Draft)

EPA Science Inventory

EPA is developing an Integrated Risk Information System (IRIS) assessment of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and has released the draft assessment for public comment. When final, the assessment will appear on the IRIS database.

Cardiac-Specific SOCS3 Deletion Prevents In Vivo Myocardial Ischemia Reperfusion Injury through Sustained Activation of Cardioprotective Signaling Molecules.

PubMed

Nagata, Takanobu; Yasukawa, Hideo; Kyogoku, Sachiko; Oba, Toyoharu; Takahashi, Jinya; Nohara, Shoichiro; Minami, Tomoko; Mawatari, Kazutoshi; Sugi, Yusuke; Shimozono, Koutatsu; Pradervand, Sylvain; Hoshijima, Masahiko; Aoki, Hiroki; Fukumoto, Yoshihiro; Imaizumi, Tsutomu

2015-01-01

Myocardial ischemia reperfusion injury (IRI) adversely affects cardiac performance and the prognosis of patients with acute myocardial infarction. Although myocardial signal transducer and activator of transcription (STAT) 3 is potently cardioprotective during IRI, the inhibitory mechanism responsible for its activation is largely unknown. The present study aimed to investigate the role of the myocardial suppressor of cytokine signaling (SOCS)-3, an intrinsic negative feedback regulator of the Janus kinase (JAK)-STAT signaling pathway, in the development of myocardial IRI. Myocardial IRI was induced in mice by ligating the left anterior descending coronary artery for 1 h, followed by different reperfusion times. One hour after reperfusion, the rapid expression of JAK-STAT-activating cytokines was observed. We precisely evaluated the phosphorylation of cardioprotective signaling molecules and the expression of SOCS3 during IRI and then induced myocardial IRI in wild-type and cardiac-specific SOCS3 knockout mice (SOCS3-CKO). The activation of STAT3, AKT, and ERK1/2 rapidly peaked and promptly decreased during IRI. This decrease correlated with the induction of SOCS3 expression up to 24 h after IRI in wild-type mice. The infarct size 24 h after reperfusion was significantly reduced in SOCS3-CKO compared with wild-type mice. In SOCS3-CKO mice, STAT3, AKT, and ERK1/2 phosphorylation was sustained, myocardial apoptosis was prevented, and the expression of anti-apoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) was augmented. Cardiac-specific SOCS3 deletion led to the sustained activation of cardioprotective signaling molecules including and prevented myocardial apoptosis and injury during IRI. Our findings suggest that SOCS3 may represent a key factor that exacerbates the development of myocardial IRI.

Cardiac-Specific SOCS3 Deletion Prevents In Vivo Myocardial Ischemia Reperfusion Injury through Sustained Activation of Cardioprotective Signaling Molecules

PubMed Central

Nagata, Takanobu; Yasukawa, Hideo; Kyogoku, Sachiko; Oba, Toyoharu; Takahashi, Jinya; Nohara, Shoichiro; Minami, Tomoko; Mawatari, Kazutoshi; Sugi, Yusuke; Shimozono, Koutatsu; Pradervand, Sylvain; Hoshijima, Masahiko; Aoki, Hiroki; Fukumoto, Yoshihiro; Imaizumi, Tsutomu

2015-01-01

Myocardial ischemia reperfusion injury (IRI) adversely affects cardiac performance and the prognosis of patients with acute myocardial infarction. Although myocardial signal transducer and activator of transcription (STAT) 3 is potently cardioprotective during IRI, the inhibitory mechanism responsible for its activation is largely unknown. The present study aimed to investigate the role of the myocardial suppressor of cytokine signaling (SOCS)-3, an intrinsic negative feedback regulator of the Janus kinase (JAK)-STAT signaling pathway, in the development of myocardial IRI. Myocardial IRI was induced in mice by ligating the left anterior descending coronary artery for 1 h, followed by different reperfusion times. One hour after reperfusion, the rapid expression of JAK-STAT–activating cytokines was observed. We precisely evaluated the phosphorylation of cardioprotective signaling molecules and the expression of SOCS3 during IRI and then induced myocardial IRI in wild-type and cardiac-specific SOCS3 knockout mice (SOCS3-CKO). The activation of STAT3, AKT, and ERK1/2 rapidly peaked and promptly decreased during IRI. This decrease correlated with the induction of SOCS3 expression up to 24 h after IRI in wild-type mice. The infarct size 24 h after reperfusion was significantly reduced in SOCS3-CKO compared with wild-type mice. In SOCS3-CKO mice, STAT3, AKT, and ERK1/2 phosphorylation was sustained, myocardial apoptosis was prevented, and the expression of anti-apoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) was augmented. Cardiac-specific SOCS3 deletion led to the sustained activation of cardioprotective signaling molecules including and prevented myocardial apoptosis and injury during IRI. Our findings suggest that SOCS3 may represent a key factor that exacerbates the development of myocardial IRI. PMID:26010537

IRIS Toxicological Review of Benzo[a]pyrene (Interagency ...

EPA Pesticide Factsheets

On August 21, 2013, the draft Toxicological Review of Benzo[a]pyrene and the draft charge to external peer reviewers were released for public review and comment. The Toxicological Review and charge were reviewed internally by EPA and by other federal agencies and White House Offices before public release. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments and the interagency science consultation materials provided to other agencies, including interagency review drafts of the IRIS Toxicological Review of Benzo[a]pyrene and the charge to external peer reviewers, are posted on this site. EPA is undertaking an update of the Integrated Risk Information System (IRIS) health assessment for benzo[a]pyrene (BaP). The outcome of this project is an updated Toxicological Review and IRIS Summary for BaP that will be entered into the IRIS database.

Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings.

PubMed

Musubire, A K; Meya, B D; Mayanja-Kizza, H; Lukande, R; Wiesner, L D; Bohjanen, P; R Boulware, R D

2012-06-01

In many resource-limited settings, cryptococcal meningitis (CM) contributes up to 20% of all deaths with further complications due to Immune Reconstitution Inflammatory Syndrome (IRIS). We present a case report on a patient who developed CM-IRIS and then subsequent CM-relapse with a fluconazole-resistant organism and then later CM-IRIS once again, manifesting as cystic cryptococcomas, hydrocephalus, and sterile CSF. In this case we, demonstrate that CM-IRIS and persistent low level cryptococcal infection are not mutually exclusive phenomena. The management of IRIS with corticosteroids may increase the risk of culture positive CM-relapse which may further increase the risk of recurrent IRIS and resulting complications including death. We also highlight the role of imaging and fluconazole resistance testing in patients with recurrent meningitis and the importance of CSF cultures in guiding treatment decisions.

Engineering a Light-Attenuating Artificial Iris

PubMed Central

Shareef, Farah J.; Sun, Shan; Kotecha, Mrignayani; Kassem, Iris; Azar, Dimitri; Cho, Michael

2016-01-01

Purpose Discomfort from light exposure leads to photophobia, glare, and poor vision in patients with congenital or trauma-induced iris damage. Commercial artificial iris lenses are static in nature to provide aesthetics without restoring the natural iris's dynamic response to light. A new photo-responsive artificial iris was therefore developed using a photochromic material with self-adaptive light transmission properties and encased in a transparent biocompatible polymer matrix. Methods The implantable artificial iris was designed and engineered using Photopia, a class of photo-responsive materials (termed naphthopyrans) embedded in polyethylene. Photopia was reshaped into annular disks that were spin-coated with polydimethylsiloxane (PDMS) to form our artificial iris lens of controlled thickness. Results Activated by UV and blue light in approximately 5 seconds with complete reversal in less than 1 minute, the artificial iris demonstrates graded attenuation of up to 40% of visible and 60% of UV light. There optical characteristics are suitable to reversibly regulate the incident light intensity. In vitro cell culture experiments showed up to 60% cell death within 10 days of exposure to Photopia, but no significant cell death observed when cultured with the artificial iris with protective encapsulation. Nuclear magnetic resonance spectroscopy confirmed these results as there was no apparent leakage of potentially toxic photochromic material from the ophthalmic device. Conclusions Our artificial iris lens mimics the functionality of the natural iris by attenuating light intensity entering the eye with its rapid reversible change in opacity and thus potentially providing an improved treatment option for patients with iris damage. PMID:27116547

Engineering a Light-Attenuating Artificial Iris.

PubMed

Shareef, Farah J; Sun, Shan; Kotecha, Mrignayani; Kassem, Iris; Azar, Dimitri; Cho, Michael

2016-04-01

Discomfort from light exposure leads to photophobia, glare, and poor vision in patients with congenital or trauma-induced iris damage. Commercial artificial iris lenses are static in nature to provide aesthetics without restoring the natural iris's dynamic response to light. A new photo-responsive artificial iris was therefore developed using a photochromic material with self-adaptive light transmission properties and encased in a transparent biocompatible polymer matrix. The implantable artificial iris was designed and engineered using Photopia, a class of photo-responsive materials (termed naphthopyrans) embedded in polyethylene. Photopia was reshaped into annular disks that were spin-coated with polydimethylsiloxane (PDMS) to form our artificial iris lens of controlled thickness. Activated by UV and blue light in approximately 5 seconds with complete reversal in less than 1 minute, the artificial iris demonstrates graded attenuation of up to 40% of visible and 60% of UV light. There optical characteristics are suitable to reversibly regulate the incident light intensity. In vitro cell culture experiments showed up to 60% cell death within 10 days of exposure to Photopia, but no significant cell death observed when cultured with the artificial iris with protective encapsulation. Nuclear magnetic resonance spectroscopy confirmed these results as there was no apparent leakage of potentially toxic photochromic material from the ophthalmic device. Our artificial iris lens mimics the functionality of the natural iris by attenuating light intensity entering the eye with its rapid reversible change in opacity and thus potentially providing an improved treatment option for patients with iris damage.

Morphological Alterations Within the Peripheral Fixation of the Iris Dilator Muscle in Eyes With Pigmentary Glaucoma

PubMed Central

Flügel-Koch, Cassandra M.; Tektas, Ozan Y.; Kaufman, Paul L.; Paulsen, Friedrich P.; Lütjen-Drecoll, Elke

2014-01-01

Purpose. To analyze the peripheral fixation of the iris dilator muscle in normal eyes and in eyes with pigmentary glaucoma (PG). Methods. Using 63 control eyes (age 18 months–99 years), the peripheral iris dilator was investigated by light microscopy, immunohistochemistry, and electron microscopy. Development was studied using 18 differently aged fetal eyes stained immunohistochemically against α-smooth muscle (SM) actin. The peripheral iris dilator muscle in PG was analyzed using semithin and ultrathin sections of six glutaraldehyde-fixed eyes from three donors aged 38, 62, and 74 years. Results. In normal eyes, the peripheral end of the iris dilator muscle is arranged in a sphincter-like manner. Arcade-shaped tendinous connections associated with myofibroblasts (iridial strands) anchor the iris dilator within the elastic–fibromuscular ciliary meshwork that also serves as fixation area for the elastic tendons of the inner ciliary muscle portions. The iridial strands are innervated and can adapt their length during accommodation. The PG eyes show incomplete circular bundles and iridial strands that are mainly anchored to the iris stroma and the flexible uveal parts of the trabecular meshwork. Conclusions. The normal anchorage of the peripheral iris dilator and its presumably neuronally regulated length adaptation stabilize the peripheral iris during accommodation. Insufficient fixation in PG could promote posterior bowing of the iris with rubbing against the zonular fibers and pigment liberation from the iris pigmented epithelium. PMID:24938519

Assessment of Urbanization on the Integrated Land-Ocean-Atmosphere Environment in Coastal Metropolis in Preparation for HyspIRI

NASA Technical Reports Server (NTRS)

Sequera, Pedro; McDonald, Kyle C.; Gonzalez, Jorge; Arend, Mark; Krakauer, Nir; Bornstein, Robert; Luvll, Jeffrey

2012-01-01

The need for comprehensive studies of the relationships between past and projected changes of regional climate and human activity in comple x urban environments has been well established. The HyspIRI preparato ry airborne activities in California, associated science and applicat ions research, and eventually HyspIRI itself provide an unprecedented opportunity for development and implementation of an integrated data and modeling analysis system focused on coastal urban environments. We will utilize HyspIRI preparatory data collections in developing ne w remote sensing-based tools for investigating the integrated urban e nvironment, emphasizing weather, climate, and energy demands in compl ex coastal cities.

IRIS Toxicological Review of Ammonia Noncancer Inhalation ...

EPA Pesticide Factsheets

In September 2016, EPA finalized the IRIS assessment of Ammonia (Noncancer Inhalation). The Toxicological Review was reviewed internally by EPA and by other federal agencies and White House Offices before public release in June 2016. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments and the interagency science discussion materials provided to other agencies, including interagency review drafts of the IRIS Toxicological Review of Ammonia (Noncancer Inhalation) are posted on this site. Note: No major science comments were received on the Interagency Science Discussion Draft. EPA is undertaking an Integrated Risk Information System (IRIS) health assessment for ammonia. IRIS is an EPA database containing Agency scientific positions on potential adverse human health effects that may result from chronic (or lifetime) exposure to chemicals in the environment. IRIS contains chemical-specific summaries of qualitative and quantitative health information in support of two steps of the risk assessment paradigm, i.e., hazard identification and dose-response evaluation. IRIS assessments are used in combination with specific situational exposure assessment information to evaluate potential public health risk associated with environmental contaminants.

VASIR: An Open-Source Research Platform for Advanced Iris Recognition Technologies.

PubMed

Lee, Yooyoung; Micheals, Ross J; Filliben, James J; Phillips, P Jonathon

2013-01-01

The performance of iris recognition systems is frequently affected by input image quality, which in turn is vulnerable to less-than-optimal conditions due to illuminations, environments, and subject characteristics (e.g., distance, movement, face/body visibility, blinking, etc.). VASIR (Video-based Automatic System for Iris Recognition) is a state-of-the-art NIST-developed iris recognition software platform designed to systematically address these vulnerabilities. We developed VASIR as a research tool that will not only provide a reference (to assess the relative performance of alternative algorithms) for the biometrics community, but will also advance (via this new emerging iris recognition paradigm) NIST's measurement mission. VASIR is designed to accommodate both ideal (e.g., classical still images) and less-than-ideal images (e.g., face-visible videos). VASIR has three primary modules: 1) Image Acquisition 2) Video Processing, and 3) Iris Recognition. Each module consists of several sub-components that have been optimized by use of rigorous orthogonal experiment design and analysis techniques. We evaluated VASIR performance using the MBGC (Multiple Biometric Grand Challenge) NIR (Near-Infrared) face-visible video dataset and the ICE (Iris Challenge Evaluation) 2005 still-based dataset. The results showed that even though VASIR was primarily developed and optimized for the less-constrained video case, it still achieved high verification rates for the traditional still-image case. For this reason, VASIR may be used as an effective baseline for the biometrics community to evaluate their algorithm performance, and thus serves as a valuable research platform.

VASIR: An Open-Source Research Platform for Advanced Iris Recognition Technologies

PubMed Central

Lee, Yooyoung; Micheals, Ross J; Filliben, James J; Phillips, P Jonathon

2013-01-01

The performance of iris recognition systems is frequently affected by input image quality, which in turn is vulnerable to less-than-optimal conditions due to illuminations, environments, and subject characteristics (e.g., distance, movement, face/body visibility, blinking, etc.). VASIR (Video-based Automatic System for Iris Recognition) is a state-of-the-art NIST-developed iris recognition software platform designed to systematically address these vulnerabilities. We developed VASIR as a research tool that will not only provide a reference (to assess the relative performance of alternative algorithms) for the biometrics community, but will also advance (via this new emerging iris recognition paradigm) NIST’s measurement mission. VASIR is designed to accommodate both ideal (e.g., classical still images) and less-than-ideal images (e.g., face-visible videos). VASIR has three primary modules: 1) Image Acquisition 2) Video Processing, and 3) Iris Recognition. Each module consists of several sub-components that have been optimized by use of rigorous orthogonal experiment design and analysis techniques. We evaluated VASIR performance using the MBGC (Multiple Biometric Grand Challenge) NIR (Near-Infrared) face-visible video dataset and the ICE (Iris Challenge Evaluation) 2005 still-based dataset. The results showed that even though VASIR was primarily developed and optimized for the less-constrained video case, it still achieved high verification rates for the traditional still-image case. For this reason, VASIR may be used as an effective baseline for the biometrics community to evaluate their algorithm performance, and thus serves as a valuable research platform. PMID:26401431

Tools for Integrating Data Access from the IRIS DMC into Research Workflows

NASA Astrophysics Data System (ADS)

Reyes, C. G.; Suleiman, Y. Y.; Trabant, C.; Karstens, R.; Weertman, B. R.

2012-12-01

Web service interfaces at the IRIS Data Management Center (DMC) provide access to a vast archive of seismological and related geophysical data. These interfaces are designed to easily incorporate data access into data processing workflows. Examples of data that may be accessed include: time series data, related metadata, and earthquake information. The DMC has developed command line scripts, MATLAB® interfaces and a Java library to support a wide variety of data access needs. Users of these interfaces do not need to concern themselves with web service details, networking, or even (in most cases) data conversion. Fetch scripts allow access to the DMC archive and are a comfortable fit for command line users. These scripts are written in Perl and are well suited for automation and integration into existing workflows on most operating systems. For metdata and event information, the Fetch scripts even parse the returned data into simple text summaries. The IRIS Java Web Services Library (IRIS-WS Library) allows Java developers the ability to create programs that access the DMC archives seamlessly. By returning the data and information as native Java objects the Library insulates the developer from data formats, network programming and web service details. The MATLAB interfaces leverage this library to allow users access to the DMC archive directly from within MATLAB (r2009b or newer), returning data into variables for immediate use. Data users and research groups are developing other toolkits that use the DMC's web services. Notably, the ObsPy framework developed at LMU Munich is a Python Toolbox that allows seamless access to data and information via the DMC services. Another example is the MATLAB-based GISMO and Waveform Suite developments that can now access data via web services. In summary, there now exist a host of ways that researchers can bring IRIS DMC data directly into their workflows. MATLAB users can use irisFetch.m, command line users can use the various Fetch scripts, Java users can use the IRIS-WS library, and Python users may request data through ObsPy. To learn more about any of these clients see http://www.iris.edu/ws/wsclients/.

Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART.

PubMed

Karmakar, Suman; Sharma, Surendra K; Vashishtha, Richa; Sharma, Abhishek; Ranjan, Sanjay; Gupta, Deepak; Sreenivas, Vishnubhatla; Sinha, Sanjeev; Biswas, Ashutosh; Gulati, Vinay

2011-01-01

IRIS is an important complication that occurs during management of HIV-TB coinfection and it poses difficulty in diagnosis. Previous studies have reported variable incidence of IRIS. The present study was undertaken to describe the pattern of TB-associated IRIS using recently proposed consensus case-definitions for TB-IRIS for its use in resource-limited settings. A prospective analysis of ART-naïve adults started on HAART from November, 2008 to May, 2010 was done in a tertiary care hospital in north India. A total 224 patients divided into two groups, one with HIV-TB and the other with HIV alone, were followedup for a minimum period of 3 months. The diagnosis of TB was categorised as ''definitive" and ''probable". Out of a total of 224 patients, 203 completed followup. Paradoxical TB-IRIS occurred in 5 of 123 (4%) HIV-TB patients while 6 of 80 (7.5%) HIV patients developed ART-associated TB. A reduction in plasma viral load was significantly (P = .016) associated with paradoxical TB-IRIS. No identifiable risk factors were associated with the development of ART-associated TB. The consensus case-definitions are useful tools in the diagnosis of TB-associated IRIS. High index of clinical suspicion is required for an early diagnosis.

Towards online iris and periocular recognition under relaxed imaging constraints.

PubMed

Tan, Chun-Wei; Kumar, Ajay

2013-10-01

Online iris recognition using distantly acquired images in a less imaging constrained environment requires the development of a efficient iris segmentation approach and recognition strategy that can exploit multiple features available for the potential identification. This paper presents an effective solution toward addressing such a problem. The developed iris segmentation approach exploits a random walker algorithm to efficiently estimate coarsely segmented iris images. These coarsely segmented iris images are postprocessed using a sequence of operations that can effectively improve the segmentation accuracy. The robustness of the proposed iris segmentation approach is ascertained by providing comparison with other state-of-the-art algorithms using publicly available UBIRIS.v2, FRGC, and CASIA.v4-distance databases. Our experimental results achieve improvement of 9.5%, 4.3%, and 25.7% in the average segmentation accuracy, respectively, for the UBIRIS.v2, FRGC, and CASIA.v4-distance databases, as compared with most competing approaches. We also exploit the simultaneously extracted periocular features to achieve significant performance improvement. The joint segmentation and combination strategy suggest promising results and achieve average improvement of 132.3%, 7.45%, and 17.5% in the recognition performance, respectively, from the UBIRIS.v2, FRGC, and CASIA.v4-distance databases, as compared with the related competing approaches.

75 FR 30825 - Draft Toxicological Review of Formaldehyde in Support of Summary Information on the Integrated...

Federal Register 2010, 2011, 2012, 2013, 2014

2010-06-02

... session is to allow all interested parties to present scientific and technical comments on draft IRIS..., they should also submit written comments at least 5 working days before the meeting date announced on... August 31, 2010. Comments should be in writing and must be received by EPA by August 31, 2010. The...

76 FR 60827 - Draft Toxicological Review of Biphenyl: In Support of Summary Information on the Integrated Risk...

Federal Register 2010, 2011, 2012, 2013, 2014

2011-09-30

... to present scientific and technical comments on draft IRIS health assessments to EPA and other... would like EPA to share their comments with the external peer reviewers, they should also submit written..., and ends November 29, 2011. Comments should be in writing and must be received by EPA by November 29...

Long-term results after artificial iris implantation in patients with aniridia.

PubMed

Rickmann, Annekatrin; Szurman, Peter; Januschowski, Kai; Waizel, Maria; Spitzer, Martin S; Boden, Karl T; Szurman, Gesine B

2016-07-01

The custom-made, flexible artificial iris developed by HumanOptics and Koch can reconstruct the anterior segment of patients with aniridia. The aim of this study was to evaluate the long-term clinical outcome and complication spectrum after artificial iris implantation and the role of the embedded fiber mesh in view of specific complications. In this retrospective interventional case series, patients received an artificial iris between 2004 and 2013. Only eyes with a minimum follow-up period of 2 years were included. Indications were congenital, traumatic, or iatrogenic aniridia. The artificial iris was used either with or without embedded fiber mesh for partial or full prostheses. We included 34 patients (mean age 48.8 years; SD ±17.2) with a mean follow-up of 50.0 months (SD ±18.9 months). No repositioning of prostheses was necessary. In cases of keratopathy (17.6 %) visual function increased from baseline mean 1.6 logMAR (SD ±0.7) to 1.2 logMAR (SD ±0.7) after artificial iris implantation. The remaining iris tissue darkened during the follow-up in 23.5 % (83.3 % with and 10.7 % without mesh), 8.8 % developed glaucoma (50 % with and 0 % without mesh) and 14.7 % needed consecutive surgery after prostheses implantation (50 % with and 7.1 % without mesh). In three out of seven trauma cases (42.9 %) silicone oil was spilled into the anterior chamber after 2.5 years on average. The artificial iris prosthesis revealed a good clinical outcome in terms of long-term stability, cosmetic appearance, visual function, and represents a good functional iris diaphragm for compartmentalisation. Complications such as glaucoma, darkening of iris tissue, and need for consecutive anterior segment surgery are clearly associated with implants with integrated fiber mesh, but not to those without. Hence, the use of full iris prostheses without embedded fiber mesh, even in cases with remnant iris, and the use of slightly smaller implants than officially recommended may be beneficial.

Cross-sensor iris recognition through kernel learning.

PubMed

Pillai, Jaishanker K; Puertas, Maria; Chellappa, Rama

2014-01-01

Due to the increasing popularity of iris biometrics, new sensors are being developed for acquiring iris images and existing ones are being continuously upgraded. Re-enrolling users every time a new sensor is deployed is expensive and time-consuming, especially in applications with a large number of enrolled users. However, recent studies show that cross-sensor matching, where the test samples are verified using data enrolled with a different sensor, often lead to reduced performance. In this paper, we propose a machine learning technique to mitigate the cross-sensor performance degradation by adapting the iris samples from one sensor to another. We first present a novel optimization framework for learning transformations on iris biometrics. We then utilize this framework for sensor adaptation, by reducing the distance between samples of the same class, and increasing it between samples of different classes, irrespective of the sensors acquiring them. Extensive evaluations on iris data from multiple sensors demonstrate that the proposed method leads to improvement in cross-sensor recognition accuracy. Furthermore, since the proposed technique requires minimal changes to the iris recognition pipeline, it can easily be incorporated into existing iris recognition systems.

Immune reconstitution inflammatory syndrome in HIV-infected patients with Pneumocystis jirovecii pneumonia.

PubMed

Roade Tato, Luisa; Burgos Cibrian, Joaquín; Curran Fábregas, Adrià; Navarro Mercadé, Jordi; Willekens, Rein; Martín Gómez, María Teresa; Ribera Pascuet, Esteban; Falcó Ferrer, Vicenç

2017-11-26

The incidence of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients after an episode of Pneumocystis jirovecii pneumonia (PJP) seems to be lower than with other opportunistic infections. We conducted an observational study in order to determine the incidence, clinical characteristics and outcome of patients diagnosed with PJP-related IRIS. We conducted an observational study of HIV patients diagnosed with PJP-related IRIS from January 2000 to November 2015. We analyzed epidemiological and clinical characteristics as well as laboratory findings. We also carried out a systematic review of published cases. Six cases of IRIS out of 123 (4.9%) HIV-infected patients with PJP who started ART were diagnosed. All six cases were men with a median age of 34 (IQR: 8) years. The six patients developed paradoxical IRIS. Subjects younger than 40 years old (p=0.084) and with an HIV-RNA viral load >100000 copies/ml (p=0.081) at diagnosis showed a tendency to develop IRIS. Thirty-seven published cases of PJP-related IRIS were identified. Although 51% of cases involved respiratory failure, no deaths were reported. PJP-related IRIS is rare condition compared to other opportunistic infections. It can lead to a severe respiratory failure in a significant proportion of cases, although no deaths have been reported. Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

An experimental model of ectropion uveae and iris neovascularization in the cat.

PubMed

Hjelmeland, L M; Stewart, M W; Li, J; Toth, C A; Burns, M S; Landers, M B

1992-04-01

Neovascularization of the iris (NVI) is one of the most frequently studied intraocular vascular proliferations in animal models. Ectropion uveae has not been a consistent finding in these studies. In this study, a surgical model of ectropion uveae and iris neovascularization was developed that involved lensectomy, vitrectomy, bipolar cautery and transection of all three principal branch veins in the cat eye. Twelve of 14 eyes that received this procedure developed postoperative retinal detachments with a clinical picture of hemorrhagic retinopathy. These eyes progressed to a clinical picture of NVI within 1-7 wk. Eight eyes developed ectropion uveae for as much as 300 degrees. At the light microscopic level, a fibrovascular membrane was apparent on the anterior iris stroma in 9 of 14 eyes and further involved the angle in six eyes.

Development of IR imaging system simulator

NASA Astrophysics Data System (ADS)

Xiang, Xinglang; He, Guojing; Dong, Weike; Dong, Lu

2017-02-01

To overcome the disadvantages of the tradition semi-physical simulation and injection simulation equipment in the performance evaluation of the infrared imaging system (IRIS), a low-cost and reconfigurable IRIS simulator, which can simulate the realistic physical process of infrared imaging, is proposed to test and evaluate the performance of the IRIS. According to the theoretical simulation framework and the theoretical models of the IRIS, the architecture of the IRIS simulator is constructed. The 3D scenes are generated and the infrared atmospheric transmission effects are simulated using OGRE technology in real-time on the computer. The physical effects of the IRIS are classified as the signal response characteristic, modulation transfer characteristic and noise characteristic, and they are simulated on the single-board signal processing platform based on the core processor FPGA in real-time using high-speed parallel computation method.

IRIS Toxicological Review of Tetrahydrofuran (THF) ...

EPA Pesticide Factsheets

EPA is releasing the draft report, Toxicological Review of Tetrahydrofuran, that was distributed to Federal agencies and White House Offices for comment during the Science Discussion step of the IRIS Assessment Development Process. Comments received from other Federal agencies and White House Offices are provided below with external peer review panel comments. EPA is undertaking an Integrated Risk Information System (IRIS) health assessment for tetrahydrofuran. IRIS is an EPA database containing Agency scientific positions on potential adverse human health effects that may result from chronic (or lifetime) exposure to chemicals in the environment. IRIS contains chemical-specific summaries of qualitative and quantitative health information in support of two steps of the risk assessment paradigm, i.e., hazard identification and dose-response evaluation. IRIS assessments are used in combination with specific situational exposure assessment information to evaluate potential public health risk associated with environmental contaminants.

Morphological alterations within the peripheral fixation of the iris dilator muscle in eyes with pigmentary glaucoma.

PubMed

Flügel-Koch, Cassandra M; Tektas, Ozan Y; Kaufman, Paul L; Paulsen, Friedrich P; Lütjen-Drecoll, Elke

2014-06-17

To analyze the peripheral fixation of the iris dilator muscle in normal eyes and in eyes with pigmentary glaucoma (PG). Using 63 control eyes (age 18 months-99 years), the peripheral iris dilator was investigated by light microscopy, immunohistochemistry, and electron microscopy. Development was studied using 18 differently aged fetal eyes stained immunohistochemically against α-smooth muscle (SM) actin. The peripheral iris dilator muscle in PG was analyzed using semithin and ultrathin sections of six glutaraldehyde-fixed eyes from three donors aged 38, 62, and 74 years. In normal eyes, the peripheral end of the iris dilator muscle is arranged in a sphincter-like manner. Arcade-shaped tendinous connections associated with myofibroblasts (iridial strands) anchor the iris dilator within the elastic-fibromuscular ciliary meshwork that also serves as fixation area for the elastic tendons of the inner ciliary muscle portions. The iridial strands are innervated and can adapt their length during accommodation. The PG eyes show incomplete circular bundles and iridial strands that are mainly anchored to the iris stroma and the flexible uveal parts of the trabecular meshwork. The normal anchorage of the peripheral iris dilator and its presumably neuronally regulated length adaptation stabilize the peripheral iris during accommodation. Insufficient fixation in PG could promote posterior bowing of the iris with rubbing against the zonular fibers and pigment liberation from the iris pigmented epithelium. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5 ...

EPA Pesticide Factsheets

On March 10, 2016, the public comment draft Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine and the draft charge to external peer reviewers were released for public review and comment. The Toxicological Review and charge were reviewed internally by EPA and by other federal agencies and White House Offices before public release. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments and the interagency science consultation materials provided to other agencies, including interagency review drafts of the IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine and the charge to external peer reviewers, are posted on this site. EPA is undertaking an update of the Integrated Risk Information System (IRIS) health assessment for RDX. The outcome of this project is an updated Toxicological Review and IRIS Summary for RDX that will be entered into the IRIS database.

A multi-approach feature extractions for iris recognition

NASA Astrophysics Data System (ADS)

Sanpachai, H.; Settapong, M.

2014-04-01

Biometrics is a promising technique that is used to identify individual traits and characteristics. Iris recognition is one of the most reliable biometric methods. As iris texture and color is fully developed within a year of birth, it remains unchanged throughout a person's life. Contrary to fingerprint, which can be altered due to several aspects including accidental damage, dry or oily skin and dust. Although iris recognition has been studied for more than a decade, there are limited commercial products available due to its arduous requirement such as camera resolution, hardware size, expensive equipment and computational complexity. However, at the present time, technology has overcome these obstacles. Iris recognition can be done through several sequential steps which include pre-processing, features extractions, post-processing, and matching stage. In this paper, we adopted the directional high-low pass filter for feature extraction. A box-counting fractal dimension and Iris code have been proposed as feature representations. Our approach has been tested on CASIA Iris Image database and the results are considered successful.

Characterization of iris pattern stretches and application to the measurement of roll axis eye movements.

PubMed

Nishiyama, Junpei; Hashimoto, Tsutomu; Sakashita, Yusuke; Fujiyoshi, Hironobu; Hirata, Yutaka

2008-01-01

Eye movements are utilized in many scientific studies as a probe that reflects the neural representation of 3 dimensional extrapersonal space. This study proposes a method to accurately measure the roll component of eye movements under the conditions in which the pupil diameter changes. Generally, the iris pattern matching between a reference and a test iris image is performed to estimate roll angle of the test image. However, iris patterns are subject to change when the pupil size changes, thus resulting in less accurate roll angle estimation if the pupil sizes in the test and reference images are different. We characterized non-uniform iris pattern contraction/expansion caused by pupil dilation/constriction, and developed an algorithm to convert an iris pattern with an arbitrary pupil size into that with the same pupil size as the reference iris pattern. It was demonstrated that the proposed method improved the accuracy of the measurement of roll eye movement by up to 76.9%.

Implantation of ArtificialIris, a CustomFlex irisprosthesis, in a trauma patient with an Artisan lens

PubMed Central

Doroodgar, Farideh; Jabbarvand, Mahmoud; Niazi, Feizollah; Niazi, Sana; Sanginabadi, Azad

2017-01-01

Abstract Purpose: To evaluate probable complications of ArtificialIris implantation with iris fixated intraocular lens. Method: Development of photophobia, glare, and psychological strain during face-to-face communication in a 23-year-old man with a widespread traumatic iris defect terminate to make a decision for performing implantation of an ArtificialIris (Humanoptics, Erlangen, Germany) under the remnant iris without removing the patient's existing Artisan lens. Results: Without any intraoperative or postoperative complications, the patient's visual acuity increased by 1 line, the endothelial cell loss was comparable with the cell loss associated with standard cataract surgery, and the anterior-chamber depth and anterior-chamber anatomy did not change. At the final follow-up examination, the mean intraocular pressure did not differ from baseline, and we achieved high level of patient satisfaction and subjective vision improvement. We discuss the particular importance of considering the patient's expectations, the appropriate measurements, ways to perfect color evaluation, and the types of ArtificialIris products. Conclusion: The implantation of the ArtificialIris in patients with aphakic iris-supported lenses (ie, pre-existing Artisan lenses) is a feasible approach and a useful option for patients with thin irises and iris hypoplasia who are at risk of subluxation or the dislocation of the posterior-chamber intraocular lens (PCIOL), and also those with sclerally fixed PCIOLs. PMID:29137026

Edge detection techniques for iris recognition system

NASA Astrophysics Data System (ADS)

Tania, U. T.; Motakabber, S. M. A.; Ibrahimy, M. I.

2013-12-01

Nowadays security and authentication are the major parts of our daily life. Iris is one of the most reliable organ or part of human body which can be used for identification and authentication purpose. To develop an iris authentication algorithm for personal identification, this paper examines two edge detection techniques for iris recognition system. Between the Sobel and the Canny edge detection techniques, the experimental result shows that the Canny's technique has better ability to detect points in a digital image where image gray level changes even at slow rate.

The Infrared Imaging Spectrograph (IRIS) for TMT: multi-tiered wavefront measurements and novel mechanical design

NASA Astrophysics Data System (ADS)

Dunn, Jennifer; Andersen, David; Chapin, Edward; Reshetov, Vlad; Wierzbicki, Ramunas; Herriot, Glen; Chalmer, Dean; Isbrucker, Victor; Larkin, James E.; Moore, Anna M.; Suzuki, Ryuji

2016-08-01

The InfraRed Imaging Spectrograph (IRIS) will be the first light adaptive optics instrument on the Thirty Meter Telescope (TMT). IRIS is being built by a collaboration between Caltech, the University of California, NAOJ and NRC Herzberg. In this paper we present novel aspects of the Support Structure, Rotator and On-Instrument Wavefront Sensor systems being developed at NRC Herzberg. IRIS is suspended from the bottom port of the Narrow Field Infrared Adaptive Optics System (NFIRAOS), and provides its own image de-rotation to compensate for sidereal rotation of the focal plane. This arrangement is a challenge because NFIRAOS is designed to host two other science instruments, which imposes strict mass requirements on IRIS. As the mechanical design of all elements has progressed, we have been tasked with keeping the instrument mass under seven tonnes. This requirement has resulted in a mass reduction of 30 percent for the support structure and rotator compared to the most recent IRIS designs. To accomplish this goal, while still being able to withstand earthquakes, we developed a new design with composite materials. As IRIS is a client instrument of NFIRAOS, it benefits from NFIRAOS's superior AO correction. IRIS plays an important role in providing this correction by sensing low-order aberrations with three On-Instrument Wavefront Sensors (OIWFS). The OIWFS consists of three independently positioned natural guide star wavefront sensor probe arms that patrol a 2-arcminute field of view. We expect tip-tilt measurements from faint stars within the IRIS imager focal plane will further stabilize the delivered image quality. We describe how the use of On-Detector Guide Windows (ODGWs) in the IRIS imaging detector can be incorporated into the AO correction. In this paper, we present our strategies for acquiring and tracking sources with this complex AO system, and for mitigating and measuring the various potential sources of image blur and misalignment due to properties of the mechanical structure and interfaces.

The Prototype HyspIRI Thermal Infrared Radiometer (PHyTIR): A High Speed, Multispectral, Thermal Instrument Development in Support of HyspIRI-TIR

NASA Technical Reports Server (NTRS)

Hook, Simon

2011-01-01

The Prototype HyspIRI Thermal Infrared Radiometer (PHyTIR) is being developed as part of the risk reduction activities associated with the Hyperspectral Infrared Imager (HyspIRI). The HyspIRI mission was recommended by the National Research Council Decadal Survey and includes a visible shortwave infrared (SWIR) pushboom spectrometer and a multispectral whiskbroom thermal infrared (TIR) imager. Data from the HyspIRI mission will be used to address key science questions related to the Solid Earth and Carbon Cycle and Ecosystems focus areas of the NASA Science Mission Directorate. The HyspIRI TIR system will have 60m ground resolution, better than 200mK noise equivalent delta temperature (NEDT), 0.5C absolute temperature resolution with a 5-day repeat from LEO orbit. PHyTIR addresses the technology readiness level (TRL) of certain key subsystems of the TIR imager, primarily the detector assembly and scanning mechanism. PHyTIR will use Mercury Cadmium Telluride (MCT) technology at the focal plane and operate in time delay integration mode. A custom read out integrated circuit (ROIC) will provide the high speed readout hence allowing the high data rates needed for the 5 day repeat. PHyTIR will also demonstrate a newly developed interferometeric metrology system. This system will provide an absolute measurement of the scanning mirror to an order of magnitude better than conventional optical encoders. This will minimize the reliance on ground control points hence minimizing post-processing (e.g. geo-rectification computations).

HIV Immune Recovery Inflammatory Syndrome and Central Nervous System Paracoccidioidomycosis.

PubMed

de Almeida, Sérgio Monteiro; Roza, Thiago Henrique

2017-04-01

The immune reconstitution inflammatory syndrome (IRIS) is a deregulated inflammatory response to invading microorganisms. It is manifested when there is an abrupt change in host immunity from an anti-inflammatory and immunosuppressive state to a pro-inflammatory state as a result of rapid depletion or removal of factors that promote immune suppression or inhibition of inflammation. The aim of this paper is to discuss and re-interpret the possibility of association of paracoccidioidomycosis (PCM) with IRIS in the central nervous system (CNS) in a case from Brazil published by Silva-Vergara ML. et al. (Mycopathologia 177:137-141, 6). An AIDS patient who was not receiving medical care developed pulmonary PCM successfully treated with itraconazole. The patient developed central nervous system PCM (NPCM) after starting the ARV therapy with recovery of immunity and control of HIV viral load, although it was not interpreted as IRIS by the authors, it fulfills the criteria for CNS IRIS. This could be the first case of NPCM associated with IRIS described. Although not frequent, IRIS must be considered in PCM patients and HIV, from endemic areas or patients that traveled to endemic areas, receiving ARV treatment and with worsening symptoms.

Clinical Characteristics of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in North Indian Population of HIV/AIDS Patients Receiving HAART

PubMed Central

Karmakar, Suman; Sharma, Surendra K.; Vashishtha, Richa; Sharma, Abhishek; Ranjan, Sanjay; Gupta, Deepak; Sreenivas, Vishnubhatla; Sinha, Sanjeev; Biswas, Ashutosh; Gulati, Vinay

2011-01-01

Background & Objective. IRIS is an important complication that occurs during management of HIV-TB coinfection and it poses difficulty in diagnosis. Previous studies have reported variable incidence of IRIS. The present study was undertaken to describe the pattern of TB-associated IRIS using recently proposed consensus case-definitions for TB-IRIS for its use in resource-limited settings. Methods. A prospective analysis of ART-naïve adults started on HAART from November, 2008 to May, 2010 was done in a tertiary care hospital in north India. A total 224 patients divided into two groups, one with HIV-TB and the other with HIV alone, were followedup for a minimum period of 3 months. The diagnosis of TB was categorised as ‘‘definitive” and ‘‘probable”. Results. Out of a total of 224 patients, 203 completed followup. Paradoxical TB-IRIS occurred in 5 of 123 (4%) HIV-TB patients while 6 of 80 (7.5%) HIV patients developed ART-associated TB. A reduction in plasma viral load was significantly (P = .016) associated with paradoxical TB-IRIS. No identifiable risk factors were associated with the development of ART-associated TB. Conclusion. The consensus case-definitions are useful tools in the diagnosis of TB-associated IRIS. High index of clinical suspicion is required for an early diagnosis. PMID:21197457

IRIS Toxicological Review of 1,4-Dioxane (with Inhalation ...

EPA Pesticide Factsheets

On September 9, 2011, the Toxicological Review of 1,4-Dioxane (inhalation) (External Review Draft) was posted for external peer review and public comment. Subsequently, the Toxicological Review and IRIS Summary were reviewed internally by EPA and by other federal agencies and Executive Office of the President before final public release. Based on the 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and the Executive Office of the President will be made publicly available. Accordingly, interagency comments with EPA's response and the interagency science discussion draft of the IRIS Toxicological Review of 1,4-dioxane (with inhalation update) and the draft IRIS Summary are posted on this site. The Toxicological Review of 1,4-dioxane provides scientific support and rationale for the hazard and dose-response assessment pertaining to chronic exposure to 1,4-dioxane.

IRIS family of IRCCD thermal imagers integrating long-life cryogenic coolers, sophisticated algorithms for image enhancement, and hot points detection

NASA Astrophysics Data System (ADS)

Dupuy, Pascal; Harter, Jean

1995-09-01

Iris is a modular infrared thermal image developed by SAGEM since 1988, based on a 288 by 4 IRCCD detector. The first section of the presentation gives a description of the different modules of the IRIS thermal imager and their evolution in recent years. The second section covers the description of the major evolution, namely the integrated detector cooler assembly (IDCA), using a SOFRADIR 288 by 4 detector and a SAGEM microcooler, now integrated in the IRIS thermal imagers. The third section gives the description of two functions integrated in the IRIS thermal imager: (1) image enhancement, using a digital convolution filter, and (2) automatic hot points detection and tracking, offering an assistance to surveillance and automatic detection. The last section presents several programs for navy, air forces, and land applications for which IRIS has already been selected and achieved.

Final Report from the External Peer Review of the IRIS ...

EPA Pesticide Factsheets

This document is the final report for the 2004 external peer review for the EPA IRIS Reassessment of the Inhalation Carcinogenicity of Naphthalene, prepared by the Office of Research and Development's National Center for Environmental Assessment (NCEA), for the Integrated Risk Information System (IRIS) Database. A panel of external peer reviewers met to discuss the IRIS report and their responses to the charge questions on July 30, 2004. This document contains the final written comments of the external peer reviewers. This document is the final report for the 2004 external peer review for the IRIS Reassessment of the Inhalation Carcinogenicity of Naphthalene, prepared by the U.S. Environmental Protection Agency (EPA), National Center for Environmental Assessment (NCEA), for the Integrated Risk Information System (IRIS). A panel of external peer reviewers met to discuss their responses to the charge questions on July 30, 2004. This document contains the final written comments of the external peer reviewers.

Background Perchlorate Source Identification Technical Guidance

DTIC Science & Technology

2013-12-01

Sciences Branch (Code 71752) of the Advanced Systems and Applied Sciences Division (Code 71700), Space and Naval Warfare Systems Center (SSC Pacific), San...Head Advanced Systems & Applied Sciences Division iii EXECUTIVE SUMMARY The objective of this document is to outline the approach, tools, and...Helium HMX Octahydro-1,3,5,7-Tetranitro-1,3,5,7- Tetrazocine IR Installation Restoration IRIS Integrated Risk Information System IR-MS Isotope-Ratio

IRIS Toxicological Review of Ammonia (Interagency Science ...

EPA Pesticide Factsheets

On June 1, 2012, the draft Toxicological Review of Ammonia and the draft charge to external peer reviewers were released for external peer review and public comment. The Toxicological Review and charge were reviewed internally by EPA and by other federal agencies and White House Offices before public release. Consistent with the May 2009 IRIS assessment development process, all written comments on IRIS assessments submitted by other federal agencies and White House Offices are made publicly available. Accordingly, interagency comments and the interagency science consultation materials provided to other agencies, including interagency review drafts of the IRIS Toxicological Review of Ammonia and the charge to external peer reviewers, are posted on this site. EPA is undertaking an Integrated Risk Information System (IRIS) health assessment for ammonia. IRIS is an EPA database containing Agency scientific positions on potential adverse human health effects that may result from chronic (or lifetime) exposure to chemicals in the environment. IRIS contains chemical-specific summaries of qualitative and quantitative health information in support of two steps of the risk assessment paradigm, i.e., hazard identification and dose-response evaluation. IRIS assessments are used in combination with specific situational exposure assessment information to evaluate potential public health risk associated with environmental contaminants.

Development of a PCR Diagnostic System for Iris yellow spot tospovirus in Quarantine

PubMed Central

Shin, Yong-Gil; Rho, Jae-Young

2014-01-01

Iris yellow spot virus (IYSV) is a plant pathogenic virus which has been reported to continuously occur in onion bulbs, allium field crops, seed crops, lisianthus, and irises. In South Korea, IYSV is a “controlled” virus that has not been reported, and inspection is performed when crops of the genus Iris are imported into South Korea. In this study, reverse-transcription polymerase chain reaction (RT-PCR) and nested PCR inspection methods, which can detect IYSV, from imported crops of the genus Iris at quarantine sites, were developed. In addition, a modified positive plasmid, which can be used as a positive control during inspection, was developed. This modified plasmid can facilitate a more accurate inspection by enabling the examination of a laboratory contamination in an inspection system. The inspection methods that were developed in this study are expected to contribute, through the prompt and accurate inspection of IYSV at quarantine sites to the plant quarantine in South Korea. PMID:25506310

Aqueous humor tyrosinase activity is indicative of iris melanocyte toxicity.

PubMed

Mahanty, Sarmistha; Kawali, Ankush A; Dakappa, Shruthi Shirur; Mahendradas, Padmamalini; Kurian, Mathew; Kharbanda, Varun; Shetty, Rohit; Setty, Subba Rao Gangi

2017-09-01

Antibiotics such as fluoroquinolones (FQLs) are commonly used to treat ocular infections but are also known to cause dermal melanocyte toxicity. The release of dispersed pigments from the iris into the aqueous humor has been considered a possible ocular side effect of the systemic administration of FQLs such as Moxifloxacin, and this condition is known as bilateral acute iris transillumination (BAIT). Bilateral acute depigmentation of iris (BADI) is a similar condition, with iris pigment released into the aqueous, but it has not been reported as a side effect of FQL. Iris pigments are synthesized by the melanogenic enzyme tyrosinase (TYR) and can be detected but not quantified by using slit-lamp biomicroscopy. The correlation between dispersed pigments in the aqueous and the extent of melanocyte toxicity due to topical antibiotics in vivo is not well studied. Here, we aimed to study the effect of topical FQLs on iris tissue, the pigment release in the aqueous humor and the development of clinically evident iris atrophic changes. We evaluated this process by measuring the activity of TYR in the aqueous humor of 82 healthy eyes undergoing cataract surgery following topical application of FQLs such as Moxifloxacin (27 eyes, preservative-free) or Ciprofloxacin (29 eyes, with preservative) or the application of non-FQL Tobramycin (26 eyes, with preservative) as a control. In addition, the patients were questioned and examined for ocular side effects in pre- and post-operative periods. Our data showed a significantly higher mean TYR activity in the aqueous humor of Ciprofloxacin-treated eyes compared to Moxifloxacin- (preservative free, p < 0.0001) or Tobramycin-treated eyes (p < 0.0001), which indicated that few quinolones under certain conditions are toxic to the iris melanocytes. However, the reduced TYR activity in the aqueous of Moxifloxacin-treated eyes was possibly due to the presence of a higher drug concentration, which inhibits TYR activity. Consistently, immunoblotting analysis of the aqueous humor from both Ciprofloxacin- and Moxifloxacin-treated eyes showed the presence of soluble TYR enzyme, thus reflecting its toxicity to iris melanocytes and corresponding to its activity in the aqueous humor. Intriguingly, none of these patients developed any clinically appreciable ocular side effects characteristic of BAIT or BADI. Overall, our results suggest that topical antibiotics cause different levels of iris melanocyte toxicity, releasing dispersed pigments into the aqueous humor, which can be measured through TYR enzyme activity. Hence, we conclude that topical FQLs may cause subclinical toxicity to the iris melanocytes but may not be the sole cause of the development of BAIT or BADI. Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Systematic Review: Concept and Tool Development with Application in the Integrated Risk Information System (IRIS) Assessment Process

EPA Science Inventory

Systematic Review: Concept and tool development with application to the National Toxicology Program (NTP) and the Integrated Risk Information System (IRIS) Assessment Processes. There is growing interest within the environmental health community to incorporate systematic review m...

DSSTox EPA Integrated Risk Information System Structure-Index Locator File: SDF File and Documentation

EPA Science Inventory

EPA's Integrated Risk Information System (IRIS) database was developed and is maintained by EPA's Office of Research and Developement, National Center for Environmental Assessment. IRIS is a database of human health effects that may result from exposure to various substances fou...

High speed, multi-channel, thermal instrument development in support of HyspIRI-TIR

NASA Astrophysics Data System (ADS)

Johnson, William R.; Hook, Simon J.; Foote, Marc; Eng, Bjorn T.; Jau, Bruno

2011-10-01

The Jet Propulsion Laboratory is currently developing an end-to-end instrument which will provide a proof of concept prototype vehicle for a high data rate, multi-channel, thermal instrument in support of the Hyperspectral Infrared Imager (HyspIRI)-Thermal Infrared (TIR) space mission. HyspIRI mission was recommended by the National Research Council Decadal Survey (DS). The HyspIRI mission includes a visible shortwave infrared (SWIR) pushboom spectrometer and a multispectral whiskbroom thermal infrared (TIR) imager. The prototype testbed instrument addressed in this effort will only support the TIR. Data from the HyspIRI mission will be used to address key science questions related to the Solid Earth and Carbon Cycle and Ecosystems focus areas of the NASA Science Mission Directorate. Current designs for the HyspIRI-TIR space borne imager utilize eight spectral bands delineated with filters. The system will have 60m ground resolution, 200mK NEDT, 0.5C absolute temperature resolution with a 5-day repeat from LEO orbit. The prototype instrument will use mercury cadmium telluride (MCT) technology at the focal plane array in time delay integration mode. A custom read out integrated circuit (ROIC) will provide the high speed readout hence high data rates needed for the 5 day repeat. The current HyspIRI requirements dictate a ground knowledge measurement of 30m, so the prototype instrument will tackle this problem with a newly developed interferometeric metrology system. This will provide an absolute measurement of the scanning mirror to an order of magnitude better than conventional optical encoders. This will minimize the reliance on ground control points hence minimizing postprocessing (e.g. geo-rectification computations).

Developing Federated Services within Seismology: IRIS' involvement in the CoopEUS Project

NASA Astrophysics Data System (ADS)

Ahern, T. K.; Trabant, C. M.; Stults, M.

2014-12-01

As a founding member of the CoopEUS initiative, IRIS Data Services has partnered with five data centers in Europe and the UC Berkeley (NCEDC) in the US to implement internationally standardized web services to access seismological data using identical methodologies. The International Federation of Digital Seismograph Networks (FDSN) holds commission status within IASPEI/IUGG and as such is the international body that governs data exchange formats and access protocols within seismology. The CoopEUS project involves IRIS and UNAVCO as part of the EarthScope project and the European collaborators are all members of the European Plate Observing System (EPOS). CoopEUS includes one work package that attempts to coordinate data access between EarthScope and EPOS facilities. IRIS has worked with its partners in the FDSN to develop and adopt three key international service standards within seismology. These include 1) fdsn-dataselect, a service that returns time series data in a variety of standard formats, 2) fdsn-station, a service that returns related metadata about a seismic station in stationXML format, and 3) fdsn-event, a service that returns information about earthquakes and other seismic events in QuakeML format. Currently the 5 European data centers supporting these services include the ORFEUS Data Centre in the Netherlands, the GFZ German Research Centre for Geosciences in Potsdam, Germany, ETH Zurich in Switzerland, INGV in Rome, Italy, and the RESIF Data Centre in Grenoble France. Presently these seven centres can all be accessed using standardized web services with identical service calls and returns results in standardized ways. IRIS is developing an IRIS federator that will allow a client to seamlessly access information across the federated centers. Details and current status of the IRIS Federator will be presented.

Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients.

PubMed

Nouhin, Janin; Pean, Polidy; Madec, Yoann; Chevalier, Mathieu F; Didier, Celine; Borand, Laurence; Blanc, François-Xavier; Scott-Algara, Daniel; Laureillard, Didier; Weiss, Laurence

2017-05-01

Despite the high frequency of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in human immunodeficiency virus (HIV)/TB co-infected patients, no diagnostic test is available. Here, we investigated whether monocyte/macrophage activation markers can predict TB-IRIS occurrence and if they are modulated by anti-TB treatment. Frozen plasma was obtained from 127 HIV/TB co-infected adults naïve for antiretroviral therapy, enrolled in the CAMELIA trial, 36 of whom developed TB-IRIS. Concentrations of IL-1Ra, sCD14, and sCD163 were measured at anti-TB treatment onset (baseline), after 8 weeks of anti-TB treatment and at TB-IRIS time. At baseline, IL-1Ra and sCD14 concentrations were similar in TB-IRIS and non-IRIS patients. sCD163 concentrations, although significantly higher in TB-IRIS patients, did not remain associated with TB-IRIS occurrence in multivariate analysis. At the time of TB-IRIS, patients displayed higher concentrations of IL-1Ra (p = 0.002) and sCD14 (p < 0.001). The most striking result was the significant decrease in IL-1Ra after 8 weeks of anti-TB treatment (median reduction: -63% (p < 0.0001)). None of the biomarkers tested was associated with TB-IRIS occurrence. However, repeated measurement of IL-1Ra could help for the diagnosis of TB-IRIS. The substantial reduction of IL-1Ra under treatment suggests that IL-1Ra could be a surrogate biomarker of anti-TB treatment response in HIV-infected patients. Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

75 FR 16108 - Science Advisory Board Staff Office; Notification of a Public Teleconference and Public Meeting...

Federal Register 2010, 2011, 2012, 2013, 2014

2010-03-31

... Information System (IRIS) is an electronic database containing descriptive and quantitative toxicological... Office of Research and Development (ORD). In 2001, ORD developed a draft IRIS Toxicological Assessment..., the National Research Council (NRC) was requested to provide a scientific consultation on key...

Proton beam radiotherapy of iris melanoma

DOE Office of Scientific and Technical Information (OSTI.GOV)

Damato, Bertil; Kacperek, Andrzej; Chopra, Mona

2005-09-01

Purpose: To report on outcomes after proton beam radiotherapy of iris melanoma. Methods and Materials: Between 1993 and 2004, 88 patients with iris melanoma received proton beam radiotherapy, with 53.1 Gy in 4 fractions. Results: The patients had a mean age of 52 years and a median follow-up of 2.7 years. The tumors had a median diameter of 4.3 mm, involving more than 2 clock hours of iris in 32% of patients and more than 2 hours of angle in 27%. The ciliary body was involved in 20%. Cataract was present in 13 patients before treatment and subsequently developed inmore » another 18. Cataract had a 4-year rate of 63% and by Cox analysis was related to age (p = 0.05), initial visual loss (p < 0.0001), iris involvement (p < 0.0001), and tumor thickness (p < 0.0001). Glaucoma was present before treatment in 13 patients and developed after treatment in another 3. Three eyes were enucleated, all because of recurrence, which had an actuarial 4-year rate of 3.3% (95% CI 0-8.0%). Conclusions: Proton beam radiotherapy of iris melanoma is well tolerated, the main problems being radiation-cataract, which was treatable, and preexisting glaucoma, which in several patients was difficult to control.« less

An alternative method for irones quantification in iris rhizomes using headspace solid-phase microextraction.

PubMed

Roger, B; Fernandez, X; Jeannot, V; Chahboun, J

2010-01-01

The essential oil obtained from iris rhizomes is one of the most precious raw materials for the perfume industry. Its fragrance is due to irones that are gradually formed by oxidative degradation of iridals during rhizome ageing. The development of an alternative method allowing irone quantification in iris rhizomes using HS-SPME-GC. The development of the method using HS-SPME-GC was achieved using the results obtained from a conventional method, i.e. a solid-liquid extraction (SLE) followed by irone quantification by CG. Among several calibration methods tested, internal calibration gave the best results and was the least sensitive to the matrix effect. The proposed method using HS-SPME-GC is as accurate and reproducible as the conventional one using SLE. These two methods were used to monitor and compare irone concentrations in iris rhizomes that had been stored for 6 months to 9 years. Irone quantification in iris rhizome can be achieved using HS-SPME-GC. This method can thus be used for the quality control of the iris rhizomes. It offers the advantage of combining extraction and analysis with an automated device and thus allows a large number of rhizome batches to be analysed and compared in a limited amount of time. Copyright © 2010 John Wiley & Sons, Ltd.

In vivo analysis of the iris thickness by spectral domain optical coherence tomography.

PubMed

Invernizzi, Alessandro; Cigada, Mario; Savoldi, Luisa; Cavuto, Silvio; Fontana, Luigi; Cimino, Luca

2014-09-01

To assess the effectiveness of spectral domain optical coherence tomography (SD-OCT) in providing in vivo measurements of iris thickness in healthy and pathological subjects. 14 healthy volunteers and 14 patients with unilateral Fuchs' uveitis were enrolled in the study. The two groups were comparable for age, gender and race. Each subject underwent complete clinical examination and anterior segment SD-OCT imaging in both eyes. SD-OCT scans of the iris were performed following a cross-sectional pattern. Iris thickness values were obtained using a purposely developed software-based analysis of OCT images. Measurements were carried out twice by two trained independent operators to assess intraobserver and interobserver repeatability. Analysis of iris thickness was conducted in four main quadrants: superior, inferior, nasal and temporal. Iris thickness values from normal subjects were compared with the ones measured in the affected and fellow eyes of patients with Fuchs' uveitis. Iris thickness measurements showed good intraobserver and interobserver repeatability (intraclass correlation coefficient >0.971). Superior and temporal iris sectors showed respectively thickest and thinnest values in all groups. In healthy eyes, iris thickness ranged from 327.92±37.29 μm temporally to 405.25±48.49 μm superiorly. Iris thickness measurements in the affected eyes of Fuchs' uveitis patients ranged from 285.48±56.02 μm temporally to 376.12±60.97 μm superiorly. Multiple comparison analysis showed iris thickness values to be significantly lower in eyes affected by Fuchs' uveitis than both in fellow eyes (p<0.001) of the same patients and in healthy eyes (p=0.0074). SD-OCT is a suitable technique for iris thickness assessment. Thickness analysis must be carried out using a sectorial approach, taking into consideration anatomical variations existing between different iris regions. SD-OCT is a potentially useful tool for detecting iris thickness variations induced by pathological conditions such as Fuchs' uveitis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Risk factors and frequency of tuberculosis-associated immune reconstitution inflammatory syndrome among HIV/Tuberculosis co-infected patients in Southern India.

PubMed

Vignesh, Ramachandran; Swathirajan, Chinnambedu R; Solomon, Sunil S; Shankar, Esaki Muthu; Murugavel, Kailapuri G

2017-01-01

Immune reconstitution inflammatory syndrome (IRIS) continues to be a complication in HIV/tuberculosis (TB) co-infected patients initiating highly active antiretroviral therapy (HAART). The aim of this study was to evaluate the risk factors associated with developing IRIS to identify a possible biomarker to predict or diagnose IRIS in patients initiating HAART. A total of 175 HIV/TB co-infected patients initiating HAART were followed up longitudinally during September 2010 to May 2013 attending a HIV care clinic in Chennai. Patients were followed up longitudinally after HAART initiation and baseline demographic, laboratory parameters and treatment characteristics between patients with IRIS events and those without IRIS events were compared. Chi-square or Fisher's exact test for categorical variables and a Wilcoxon rank-sum test for continuous variables were performed using SPSS, version 12.0 software. Patients with IRIS had a significantly lower median baseline CD4+ T-cell count (P = 0.0039). There were no differences in terms of sex, CD4 T-cell %, plasma viral load, time interval between initiating ATT and HAART between the IRIS and non-IRIS patients. Low CD4+ T-cell count (<100 cells/μL) could be used as a marker to screen and monitor patients initiating HAART.

The infrared imaging spectrograph (IRIS) for TMT: overview of innovative science programs

NASA Astrophysics Data System (ADS)

Wright, Shelley A.; Larkin, James E.; Moore, Anna M.; Do, Tuan; Simard, Luc; Adamkovics, Maté; Armus, Lee; Barth, Aaron J.; Barton, Elizabeth; Boyce, Hope; Cooke, Jeffrey; Cote, Patrick; Davidge, Timothy; Ellerbroek, Brent; Ghez, Andrea M.; Liu, Michael C.; Lu, Jessica R.; Macintosh, Bruce A.; Mao, Shude; Marois, Christian; Schoeck, Matthias; Suzuki, Ryuji; Tan, Jonathan C.; Treu, Tommaso; Wang, Lianqi; Weiss, Jason

2014-07-01

IRIS (InfraRed Imaging Spectrograph) is a first light near-infrared diffraction limited imager and integral field spectrograph being designed for the future Thirty Meter Telescope (TMT). IRIS is optimized to perform astronomical studies across a significant fraction of cosmic time, from our Solar System to distant newly formed galaxies (Barton et al. [1]). We present a selection of the innovative science cases that are unique to IRIS in the era of upcoming space and ground-based telescopes. We focus on integral field spectroscopy of directly imaged exoplanet atmospheres, probing fundamental physics in the Galactic Center, measuring 104 to 1010 M supermassive black hole masses, resolved spectroscopy of young star-forming galaxies (1 < z < 5) and first light galaxies (6 < z < 12), and resolved spectroscopy of strong gravitational lensed sources to measure dark matter substructure. For each of these science cases we use the IRIS simulator (Wright et al. [2], Do et al. [3]) to explore IRIS capabilities. To highlight the unique IRIS capabilities, we also update the point and resolved source sensitivities for the integral field spectrograph (IFS) in all five broadband filters (Z, Y, J, H, K) for the finest spatial scale of 0.004" per spaxel. We briefly discuss future development plans for the data reduction pipeline and quicklook software for the IRIS instrument suite.

[Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].

PubMed

Kanda, Takashi

2015-07-01

The pathological findings of natalizumab-associated progressive multifocal leukoencephalopathy (PML) are reviewed. In addition to the classical pathology of PML including the presence of enlarged abnormal astrocytes, intranuclear inclusions mainly found within large swollen oligodendrocytes and abundant myelin-laden macrophages/microglia, massive perivascular and parenchymal mononuclear cell infiltration was observed. The latter pathologic picture is that of immune reconstitution inflammatory syndrome (IRIS), and most of these infiltrating cells are CD8-positive T cells. Because IRIS inevitably occurs after the cessation of natalizumab therapy due to the development of PML and subsequent plasma exchange, most of the published pathologic pictures of natalizumab-associated PML patients were a mixture of PML and PML-IRIS. PML-IRIS is also characterized by fewer oligodendroglial viral inclusions and fewer cells that are immunoreactive against anti-JCV antibodies. These findings suggest the effective removal of JCV after the return of normal immune-surveillance in the central nervous system, but clinicians should be aware that JCV elimination is not complete under the IRIS condition, and the immunosuppressive therapy against IRIS should be carefully performed. Mononuclear cell infiltration in natalizumab-associated PML-IRIS patients was much more prominent than that in HIV-associated PML-IRIS patients, reflecting the retained, even enhanced, systemic immunities in patients treated by natalizumab.

Appropriate Objective Functions for Quantifying Iris Mechanical Properties Using Inverse Finite Element Modeling.

PubMed

Pant, Anup D; Dorairaj, Syril K; Amini, Rouzbeh

2018-07-01

Quantifying the mechanical properties of the iris is important, as it provides insight into the pathophysiology of glaucoma. Recent ex vivo studies have shown that the mechanical properties of the iris are different in glaucomatous eyes as compared to normal ones. Notwithstanding the importance of the ex vivo studies, such measurements are severely limited for diagnosis and preclude development of treatment strategies. With the advent of detailed imaging modalities, it is possible to determine the in vivo mechanical properties using inverse finite element (FE) modeling. An inverse modeling approach requires an appropriate objective function for reliable estimation of parameters. In the case of the iris, numerous measurements such as iris chord length (CL) and iris concavity (CV) are made routinely in clinical practice. In this study, we have evaluated five different objective functions chosen based on the iris biometrics (in the presence and absence of clinical measurement errors) to determine the appropriate criterion for inverse modeling. Our results showed that in the absence of experimental measurement error, a combination of iris CL and CV can be used as the objective function. However, with the addition of measurement errors, the objective functions that employ a large number of local displacement values provide more reliable outcomes.

Joint Sparse Representation for Robust Multimodal Biometrics Recognition

DTIC Science & Technology

2012-01-01

described in III. Experimental evaluations on a comprehensive multimodal dataset and a face database have been described in section V. Finally, in...WVU Multimodal Dataset The WVU multimodal dataset is a comprehensive collection of different biometric modalities such as fingerprint, iris, palmprint ...Martnez and R. Benavente, “The AR face database ,” CVC Technical Report, June 1998. [29] U. Park and A. Jain, “Face matching and retrieval using soft

The IRIS Spool-Type Reactor Coolant Pump

DOE Office of Scientific and Technical Information (OSTI.GOV)

Kujawski, J.M.; Kitch, D.M.; Conway, L.E.

2002-07-01

IRIS (International Reactor Innovative and Secure) is a light water cooled, 335 MWe power reactor which is being designed by an international consortium as part of the US DOE NERI Program. IRIS features an integral reactor vessel that contains all the major reactor coolant system components including the reactor core, the coolant pumps, the steam generators and the pressurizer. This integral design approach eliminates the large coolant loop piping, and thus eliminates large loss-of-coolant accidents (LOCAs) as well as the individual component pressure vessels and supports. In addition, IRIS is being designed with a long life core and enhanced safetymore » to address the requirements defined by the US DOE for Generation IV reactors. One of the innovative features of the IRIS design is the adoption of a reactor coolant pump (called 'spool' pump) which is completely contained inside the reactor vessel. Background, status and future developments of the IRIS spool pump are presented in this paper. (authors)« less

Contribution of Different Anatomical and Physiologic Factors to Iris Contour and Anterior Chamber Angle Changes During Pupil Dilation: Theoretical Analysis

PubMed Central

Jouzdani, Sara; Amini, Rouzbeh; Barocas, Victor H.

2013-01-01

Purpose. To investigate the contribution of three anatomical and physiologic factors (dilator thickness, dynamic pupillary block, and iris compressibility) to changes in iris configuration and anterior chamber angle during pupil dilation. Methods. A mathematical model of the anterior segment based on the average values of ocular dimensions was developed to simulate pupil dilation. To change the pupil diameter from 3.0 to 5.4 mm in 10 seconds, active dilator contraction was applied by imposing stress in the dilator region. Three sets of parameters were varied in the simulations: (1) a thin (4 μm, 1% of full thickness) versus a thick dilator (covering the full thickness iris) to quantify the effects of dilator anatomy, (2) in the presence (+PB) versus absence of pupillary block (−PB) to quantify the effect of dynamic motion of aqueous humor from the posterior to the anterior chamber, and (3) a compressible versus an incompressible iris to quantify the effects of iris volume change. Changes in the apparent iris–lens contact and angle open distance (AOD500) were calculated for each case. Results. The thin case predicted a significant increase (average 700%) in iris curvature compared with the thick case (average 70%), showing that the anatomy of dilator plays an important role in iris deformation during dilation. In the presence of pupillary block (+PB), AOD500 decreased 25% and 36% for the compressible and incompressible iris, respectively. Conclusions. Iris bowing during dilation was driven primarily by posterior location of the dilator muscle and by dynamic pupillary block, but the effect of pupillary block was not as large as that of the dilator anatomy according to the quantified values of AOD500. Incompressibility of the iris, in contrast, had a relatively small effect on iris curvature but a large effect on AOD500; thus, we conclude that all three effects are important. PMID:23482467

Trichloroethylene

Integrated Risk Information System (IRIS)

Trichloroethylene ; CASRN 79 - 01 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Dichlorodifluoromethane

Integrated Risk Information System (IRIS)

Dichlorodifluoromethane ; CASRN 75 - 71 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Pentafluoroethane

Integrated Risk Information System (IRIS)

Pentafluoroethane ; CASRN 354 - 33 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Monochloramine

Integrated Risk Information System (IRIS)

Monochloramine ; CASRN 10599 - 90 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Tetrachlorocyclopentadiene

Integrated Risk Information System (IRIS)

Tetrachlorocyclopentadiene ; CASRN 695 - 77 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncar

Bromochloromethane

Integrated Risk Information System (IRIS)

Bromochloromethane ; CASRN 74 - 97 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Pentachlorobenzene

Integrated Risk Information System (IRIS)

Pentachlorobenzene ; CASRN 608 - 93 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Chlorocyclopentadiene

Integrated Risk Information System (IRIS)

Chlorocyclopentadiene ; CASRN 41851 - 50 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Tribromochloromethane

Integrated Risk Information System (IRIS)

Tribromochloromethane ; CASRN 594 - 15 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinog

Trichlorofluoromethane

Integrated Risk Information System (IRIS)

Trichlorofluoromethane ; CASRN 75 - 69 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinog

Dibromochloromethane

Integrated Risk Information System (IRIS)

Dibromochloromethane ; CASRN 124 - 48 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Trichlorocyclopentadiene

Integrated Risk Information System (IRIS)

Trichlorocyclopentadiene ; CASRN 77323 - 84 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncar

Bromodichloromethane

Integrated Risk Information System (IRIS)

Bromodichloromethane ; CASRN 75 - 27 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Pentachlorocyclopentadiene

Integrated Risk Information System (IRIS)

Pentachlorocyclopentadiene ; CASRN 25329 - 35 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Nonc

Dibromodichloromethane

Integrated Risk Information System (IRIS)

Dibromodichloromethane ; CASRN 594 - 18 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Bromotrichloromethane

Integrated Risk Information System (IRIS)

Bromotrichloromethane ; CASRN 75 - 62 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Methacrylonitrile

Integrated Risk Information System (IRIS)

Methacrylonitrile ; CASRN 126 - 98 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Chlorodifluoromethane

Integrated Risk Information System (IRIS)

Chlorodifluoromethane ; CASRN 75 - 45 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Hexachlorobenzene

Integrated Risk Information System (IRIS)

Hexachlorobenzene ; CASRN 118 - 74 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Tetrachlorovinphos

Integrated Risk Information System (IRIS)

Tetrachlorovinphos ; CASRN 961 - 11 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Pentachlorophenol

Integrated Risk Information System (IRIS)

Pentachlorophenol ; CASRN 87 - 86 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Tetraethyldithiopyrophosphate

Integrated Risk Information System (IRIS)

Tetraethyldithiopyrophosphate ; CASRN 3689 - 24 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for No

Hexachlorobutadiene

Integrated Risk Information System (IRIS)

Hexachlorobutadiene ; CASRN 87 - 68 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

The "Pavia model" of experimental small bowel transplantation in pigs: technical variations for ischemia reperfusion injury studies.

PubMed

Alessiani, M; Cobianchi, L; Viganò, J; Dominioni, T; Bottazzi, A; Zonta, S; Dionigi, P

2014-01-01

Ischemia reperfusion injury (IRI) is a major field of study in small bowel transplantation because of its implications regarding intestinal immunity. In this study, we have introduced some variations to the described models of IRI in pigs to make possible a complete isolation of the small bowel for IRI studies. In swine, two anatomical barriers make impossible a complete isolation of the small bowel at the origin of superior mesenteric artery (SMA) and vein (SMV): the main colic vessels, which originate distally to form SMA and SMV, and the blood supply of the distal portion of the duodenum and the cephalic part of the pancreas. In a group of Large White pigs (n = 5), we have performed a complete isolation of the small bowel, including sub-total colectomy and pancreaticoduodenectomy. Both SMA and SMV were isolated at the origin from the aorta and at the junction of the splenic vein, respectively. Intestinal continuity was restored with duodenojejunal anastomosis and with ileotransverse colon anastomosis. One pig died on postoperative day 5 from intestinal occlusion due to adhesions. The remaining four pigs were killed on postoperative day 7 after an uneventful postoperative course. No complications were found at autopsy. In swine, resection of part of the pancreas and duodenum and removal of the large bowel does not affect short-term survival, allowing a full isolation of the entire small bowel mimicking the transplantation procedure. Thus, this model appears to be attractive for IRI studies in the field of intestinal transplantation. Copyright © 2014 Elsevier Inc. All rights reserved.

IRI-2016: Description and Introduction

NASA Astrophysics Data System (ADS)

Bilitza, Dieter; Watanabe, Shigeto; Truhlik, Vladimir; Altadill, David

2016-07-01

The International Reference Ionosphere (IRI) is recognized as the official standard for the ionosphere (COSPAR, URSI, ISO) and is widely used for a multitude of different applications as evidenced by the many papers in science and engineering journals that acknowledge the use of IRI (e.g., about 11% of all Radio Science papers each year and citations in 21 different journals in 2015). The improvement process of the model is continuing as new data become fully available and new modeling techniques provide a more optimal representation of the observed variation patterns. We will introduce and present the latest version of the IRI model (IRI-2016) and discuss the impact of the various improvements and new additions. Most importantly, two new models will be introduced for the F2 peak height, hmF2, that were developed based on ionosonde measurements and COSMIC radio occultation data, respectively. In addition IRI-2016 includes an improved representation of the ionosphere during the very low solar activities that were reached during the last solar minimum in 2008/2009. A number of other improvements and corrections were implemented in the model and will be discussed in this presentation. We will also report about recent IRI workshops and their findings and plans for the future.

Update On Ink Jet Proofing

NASA Astrophysics Data System (ADS)

Santos, Richard P.

1989-04-01

IRIS Graphics, Inc., is a new start-up company chartered to develop, manufacture, and market direct digital filmless color imaging systems. IRIS is pleased to have been the recipient of the Graphic Art Technologies Foundation INTERTEC '87 Award for innovative excellence. IRIS is extremely proud to have been given this honor. IRIS was incorporated in April 1984 and received its initial funding of approximately 1 million by September 1984. The first 2044 Beta unit was installed in August 1985, and the first 2044 sales were made in December 1985 to R. R. Donnelley, the largest printer in the United States, and to G. S. Litho, the largest U.S. color separation house. In May 1986, IRIS received an additional 3 million in its second round of financing. A smaller version of the 2044, the 2024 was introduced at Lasers In Graphics in September 1986. IRIS achieved additional financing in July 1987 and completed the introduction of the new breakthrough Series 3000 again at Lasers In Graphics in September 1987 in Orlando, Florida. IRIS occupies 20,000 square feet at its new location in Bedford, Massachusetts, which located off of Route 128 in the high technology area near Boston.

Role of LTA4H Polymorphism in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome Occurrence and Clinical Severity in Patients Infected with HIV.

PubMed

Narendran, Gopalan; Kavitha, Dhanasekaran; Karunaianantham, Ramesh; Gil-Santana, Leonardo; Almeida-Junior, Jilson L; Reddy, Sirasanambatti Devarajulu; Kumar, Marimuthu Makesh; Hemalatha, Haribabu; Jayanthi, Nagesh Nalini; Ravichandran, Narayanan; Krishnaraja, Raja; Prabhakar, Angamuthu; Manoharan, Tamizhselvan; Nithyananthan, Lokeswaran; Arjunan, Gunasundari; Natrajan, Mohan; Swaminathan, Soumya; Andrade, Bruno B

2016-01-01

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an inflammatory phenomenon complicating HIV management in coincidental tuberculosis (TB) infection, upon immune reconstitution driven by antiretroviral therapy (ART). Leukotriene A4 hydroxylase (LTA4H), an enzyme which converts LTA4 to LTB4, regulates the balance between the anti-inflammatory lipoxins and pro-inflammatory LTB4, with direct implications in TB-driven inflammation. In humans, a single nucleotide polymorphism (SNP) in the LTA4H promoter which regulates its transcriptional activity (rs17525495) has been identified and described to impact clinical severity of TB presentation and response to corticosteroid therapy. Notably, the role of LTA4H on TB-IRIS has not been previously evaluated. Here, we performed an exploratory investigation testing the association of LTA4H polymorphism with respect to frequency of TB-IRIS occurrence and severity of TB-IRIS presentation in HIV-TB co-infected individuals. Genotypic evaluation of the LTA4H enzyme from available samples was retrospectively correlated with clinical data captured in case sheets including IRIS details. The cohort included patients recruited from a prospective cohort study nested within a randomized clinical trial (NCT0933790) of ART-naïve HIV+ patients with newly diagnosed rifampicin sensitive pulmonary TB in South India. Frequency of the wild type genotype (CC), as well as of the mutant genotypes (CT or TT) in the IRIS and non-IRIS patients was estimated. Comparative analyses were performed between wild genotype (CC) and the mutant genotypes (CT or TT) and tested for association between the LTA4H polymorphisms and IRIS incidence and clinical severity. A total of 142 eligible ART-naïve patients were included in the analyses. Eighty-six individuals exhibited the wild genotype (CC) while 56 had mutant genotypes (43-CT and only 13-TT). Variant allele frequency was 0.23 and 0.26 in non-IRIS group and in IRIS group, respectively. Upon ART initiation, 51 patients developed IRIS while 91 did not. IRIS incidence was 34% and 37% in the wild (CC) and mutant type (CT/TT), respectively (p = 0.858) with a higher frequency of severe IRIS presentation in the mutant genotype group compared to the wild type genotype (p = 0.0006). A logistic regression model confirmed the association between the presence of CT/TT genotypes and occurrence of severe IRIS. Corticosteroid therapy successfully resolved IRIS in all cases irrespective of the LTA4H genotype. A higher incidence of severe IRIS among patients with mutant LTA4H genotypes (CT and TT) was observed compared to the wild type, despite similar IRIS incidence and immune restoration in both groups. Steroids were effective in alleviating IRIS in all the genotypes.

Nitrite

Integrated Risk Information System (IRIS)

Nitrite ; CASRN 14797 - 65 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Fenamiphos

Integrated Risk Information System (IRIS)

Fenamiphos ; CASRN 22224 - 92 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

N-Nitrosodiethanolamine

Integrated Risk Information System (IRIS)

N - Nitrosodiethanolamine ; CASRN 1116 - 54 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncar

Ally

Integrated Risk Information System (IRIS)

Ally ; CASRN 74223 - 64 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Formaldehyde

Integrated Risk Information System (IRIS)

Formaldehyde ; CASRN 50 - 00 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Ethylene diamine

Integrated Risk Information System (IRIS)

Ethylene diamine ; CASRN 107 - 15 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

4-Aminopyridine

Integrated Risk Information System (IRIS)

4 - Aminopyridine ; CASRN 504 - 24 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Nickel, soluble salts

Integrated Risk Information System (IRIS)

Nickel , soluble salts ; CASRN Various Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Acetaldehyde

Integrated Risk Information System (IRIS)

Acetaldehyde ; CASRN 75 - 07 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Cyanazine

Integrated Risk Information System (IRIS)

Cyanazine ; CASRN 21725 - 46 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Carbonyl sulfide

Integrated Risk Information System (IRIS)

Carbonyl sulfide ; CASRN 463 - 58 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Xylenes

Integrated Risk Information System (IRIS)

Xylenes ; CASRN 1330 - 20 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Diazomethane

Integrated Risk Information System (IRIS)

Diazomethane ; CASRN 334 - 88 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Hydroquinone

Integrated Risk Information System (IRIS)

Hydroquinone ; CASRN 123 - 31 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Endosulfan

Integrated Risk Information System (IRIS)

Endosulfan ; CASRN 115 - 29 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Vanadium pentoxide

Integrated Risk Information System (IRIS)

Vanadium pentoxide ; CASRN 1314 - 62 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Styrene

Integrated Risk Information System (IRIS)

Styrene ; CASRN 100 - 42 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Anthracene

Integrated Risk Information System (IRIS)

Anthracene ; CASRN 120 - 12 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Carbofuran

Integrated Risk Information System (IRIS)

Carbofuran ; CASRN 1563 - 66 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Prometon

Integrated Risk Information System (IRIS)

Prometon ; CASRN 1610 - 18 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Nickel subsulfide

Integrated Risk Information System (IRIS)

Nickel subsulfide ; CASRN 12035 - 72 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Aluminum phosphide

Integrated Risk Information System (IRIS)

Aluminum phosphide ; CASRN 20859 - 73 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Rotenone

Integrated Risk Information System (IRIS)

Rotenone ; CASRN 83 - 79 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Isoxaben

Integrated Risk Information System (IRIS)

Isoxaben ; CASRN 82558 - 50 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Simazine

Integrated Risk Information System (IRIS)

Simazine ; CASRN 122 - 34 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

N-Nitrosodiethylamine

Integrated Risk Information System (IRIS)

N - Nitrosodiethylamine ; CASRN 55 - 18 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Mepiquat chloride

Integrated Risk Information System (IRIS)

Mepiquat chloride ; CASRN 24307 - 26 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Fluometuron

Integrated Risk Information System (IRIS)

Fluometuron ; CASRN 2164 - 17 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Antimony

Integrated Risk Information System (IRIS)

Antimony ; CASRN 7440 - 36 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Chlorine dioxide

Integrated Risk Information System (IRIS)

Chlorine dioxide ; CASRN 10049 - 04 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Furmecyclox

Integrated Risk Information System (IRIS)

Furmecyclox ; CASRN 60568 - 05 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Fluvalinate

Integrated Risk Information System (IRIS)

Fluvalinate ; CASRN 69409 - 94 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Methyl parathion

Integrated Risk Information System (IRIS)

Methyl parathion ; CASRN 298 - 00 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Tribromodiphenyl ether

Integrated Risk Information System (IRIS)

Tribromodiphenyl ether ; CASRN 49690 - 94 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarci

Aldrin

Integrated Risk Information System (IRIS)

Aldrin ; CASRN 309 - 00 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Strychnine

Integrated Risk Information System (IRIS)

Strychnine ; CASRN 57 - 24 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Manganese

Integrated Risk Information System (IRIS)

Manganese ; CASRN 7439 - 96 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Imazaquin

Integrated Risk Information System (IRIS)

Imazaquin ; CASRN 81335 - 37 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Epichlorohydrin

Integrated Risk Information System (IRIS)

Epichlorohydrin ; CASRN 106 - 89 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

m-Dinitrobenzene

Integrated Risk Information System (IRIS)

m - Dinitrobenzene ; CASRN 99 - 65 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Chlorothalonil

Integrated Risk Information System (IRIS)

Chlorothalonil ; CASRN 1897 - 45 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Baythroid

Integrated Risk Information System (IRIS)

Baythroid ; CASRN 68359 - 37 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Acrylamide

Integrated Risk Information System (IRIS)

Acrylamide ; CASRN 79 - 06 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Chlorine

Integrated Risk Information System (IRIS)

Chlorine ; CASRN 7782 - 50 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Carbaryl

Integrated Risk Information System (IRIS)

Carbaryl ; CASRN 63 - 25 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

4-Methylphenol

Integrated Risk Information System (IRIS)

4 - Methylphenol ; CASRN 106 - 44 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Phenylmercuric acetate

Integrated Risk Information System (IRIS)

Phenylmercuric acetate ; CASRN 62 - 38 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinog

Haloxyfop-methyl

Integrated Risk Information System (IRIS)

Haloxyfop - methyl ; CASRN 69806 - 40 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Bentazon (Basagran)

Integrated Risk Information System (IRIS)

Bentazon ( Basagran ) ; CASRN 25057 - 89 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Cyanogen bromide

Integrated Risk Information System (IRIS)

Cyanogen bromide ; CASRN 506 - 68 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Permethrin

Integrated Risk Information System (IRIS)

Permethrin ; CASRN 52645 - 53 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Butylphthalyl butylglycolate (BPBG)

Integrated Risk Information System (IRIS)

Butylphthalyl butylglycolate ( BPBG ) ; CASRN 85 - 70 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments

beta-Propiolactone

Integrated Risk Information System (IRIS)

beta - Propiolactone ; CASRN 57 - 57 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Biphenthrin

Integrated Risk Information System (IRIS)

Biphenthrin ; CASRN 82657 - 04 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Fluridone

Integrated Risk Information System (IRIS)

Fluridone ; CASRN 59756 - 60 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

beta-Chloronaphthalene

Integrated Risk Information System (IRIS)

beta - Chloronaphthalene ; CASRN 91 - 58 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Quinoline

Integrated Risk Information System (IRIS)

Quinoline ; CASRN 91 - 22 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Asbestos

Integrated Risk Information System (IRIS)

Asbestos ; CASRN 1332 - 21 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Propham

Integrated Risk Information System (IRIS)

Propham ; CASRN 122 - 42 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Zineb

Integrated Risk Information System (IRIS)

Zineb ; CASRN 12122 - 67 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Hexabromobenzene

Integrated Risk Information System (IRIS)

Hexabromobenzene ; CASRN 87 - 82 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Aramite

Integrated Risk Information System (IRIS)

Aramite ; CASRN 140 - 57 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Furan

Integrated Risk Information System (IRIS)

Furan ; CASRN 110 - 00 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Bromobenzene

Integrated Risk Information System (IRIS)

Bromobenzene ; CASRN 108 - 86 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Maneb

Integrated Risk Information System (IRIS)

Maneb ; CASRN 12427 - 38 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Benomyl

Integrated Risk Information System (IRIS)

Benomyl ; CASRN 17804 - 35 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Dichloroacetic acid

Integrated Risk Information System (IRIS)

Dichloroacetic acid ; CASRN 79 - 43 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Acenaphthylene

Integrated Risk Information System (IRIS)

Acenaphthylene ; CASRN 208 - 96 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Aniline

Integrated Risk Information System (IRIS)

Aniline ; CASRN 62 - 53 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Parathion

Integrated Risk Information System (IRIS)

Parathion ; CASRN 56 - 38 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Creosote

Integrated Risk Information System (IRIS)

Creosote ; CASRN 8001 - 58 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Acenaphthene

Integrated Risk Information System (IRIS)

Acenaphthene ; CASRN 83 - 32 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Propargyl alcohol

Integrated Risk Information System (IRIS)

Propargyl alcohol ; CASRN 107 - 19 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Methamidophos

Integrated Risk Information System (IRIS)

Methamidophos ; CASRN 10265 - 92 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Cyclohexylamine

Integrated Risk Information System (IRIS)

Cyclohexylamine ; CASRN 108 - 91 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Chloroform

Integrated Risk Information System (IRIS)

Chloroform ; CASRN 67 - 66 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Quinone

Integrated Risk Information System (IRIS)

Quinone ; CASRN 106 - 51 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Dicamba

Integrated Risk Information System (IRIS)

Dicamba ; CASRN 1918 - 00 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Benzotrichloride

Integrated Risk Information System (IRIS)

Benzotrichloride ; CASRN 98 - 07 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Endothall

Integrated Risk Information System (IRIS)

Endothall ; CASRN 145 - 73 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Acetonitrile

Integrated Risk Information System (IRIS)

Acetonitrile ; CASRN 75 - 05 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Amitraz

Integrated Risk Information System (IRIS)

Amitraz ; CASRN 33089 - 61 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Propyleneimine

Integrated Risk Information System (IRIS)

Propyleneimine ; CASRN 75 - 55 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Chlorobenzene

Integrated Risk Information System (IRIS)

Chlorobenzene ; CASRN 108 - 90 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Cumene

Integrated Risk Information System (IRIS)

Cumene ; CASRN 98 - 82 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Paclobutrazol

Integrated Risk Information System (IRIS)

Paclobutrazol ; CASRN 76738 - 62 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Cadmium

Integrated Risk Information System (IRIS)

Cadmium ; CASRN 7440 - 43 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Cyclohexanone

Integrated Risk Information System (IRIS)

Cyclohexanone ; CASRN 108 - 94 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Paraquat

Integrated Risk Information System (IRIS)

Paraquat ; CASRN 1910 - 42 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Triethylamine

Integrated Risk Information System (IRIS)

Triethylamine ; CASRN 121 - 44 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Chrysene

Integrated Risk Information System (IRIS)

Chrysene ; CASRN 218 - 01 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Acetone

Integrated Risk Information System (IRIS)

Acetone ; CASRN 67 - 64 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

N-Nitrosodimethylamine

Integrated Risk Information System (IRIS)

N - Nitrosodimethylamine ; CASRN 62 - 75 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Diuron

Integrated Risk Information System (IRIS)

Diuron ; CASRN 330 - 54 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Maleic anhydride

Integrated Risk Information System (IRIS)

Maleic anhydride ; CASRN 108 - 31 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Nitrogen dioxide

Integrated Risk Information System (IRIS)

Nitrogen dioxide ; CASRN 10102 - 44 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Dibenzofuran

Integrated Risk Information System (IRIS)

Dibenzofuran ; CASRN 132 - 64 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Tridiphane

Integrated Risk Information System (IRIS)

Tridiphane ; CASRN 58138 - 08 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Octabromodiphenyl ether

Integrated Risk Information System (IRIS)

Octabromodiphenyl ether ; CASRN 32536 - 52 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarc

Danitol

Integrated Risk Information System (IRIS)

Danitol ; CASRN 39515 - 41 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Nonabromodiphenyl ether

Integrated Risk Information System (IRIS)

Nonabromodiphenyl ether ; CASRN 63936 - 56 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarc

Pyridine

Integrated Risk Information System (IRIS)

Pyridine ; CASRN 110 - 86 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Acetochlor

Integrated Risk Information System (IRIS)

Acetochlor ; CASRN 34256 - 82 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Chloramben

Integrated Risk Information System (IRIS)

Chloramben ; CASRN 133 - 90 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

White phosphorus

Integrated Risk Information System (IRIS)

White phosphorus ; CASRN 7723 - 14 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Diisopropyl methylphosphonate (DIMP)

Integrated Risk Information System (IRIS)

Diisopropyl methylphosphonate ( DIMP ) ; CASRN 1445 - 75 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessmen

Vernam

Integrated Risk Information System (IRIS)

Vernam ; CASRN 1929 - 77 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Crotonaldehyde

Integrated Risk Information System (IRIS)

Crotonaldehyde ; CASRN 123 - 73 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Methyl isocyanate

Integrated Risk Information System (IRIS)

Methyl isocyanate ; CASRN 624 - 83 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Oxadiazon

Integrated Risk Information System (IRIS)

Oxadiazon ; CASRN 19666 - 30 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Assure

Integrated Risk Information System (IRIS)

Assure ; CASRN 76578 - 14 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Phosphine

Integrated Risk Information System (IRIS)

Phosphine ; CASRN 7803 - 51 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Silver

Integrated Risk Information System (IRIS)

Silver ; CASRN 7440 - 22 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Terbacil

Integrated Risk Information System (IRIS)

Terbacil ; CASRN 5902 - 51 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Diquat

Integrated Risk Information System (IRIS)

Diquat ; CASRN 85 - 00 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Nitrate

Integrated Risk Information System (IRIS)

Nitrate ; CASRN 14797 - 55 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Caprolactam

Integrated Risk Information System (IRIS)

Caprolactam ; CASRN 105 - 60 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Baygon

Integrated Risk Information System (IRIS)

Baygon ; CASRN 114 - 26 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Acifluorfen, sodium

Integrated Risk Information System (IRIS)

Acifluorfen , sodium ; CASRN 62476 - 59 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Tetrahydrofuran

Integrated Risk Information System (IRIS)

Tetrahydrofuran ; CASRN 109 - 99 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Isophorone

Integrated Risk Information System (IRIS)

Isophorone ; CASRN 78 - 59 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Selenium sulfide

Integrated Risk Information System (IRIS)

Selenium sulfide ; CASRN 7446 - 34 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Tricresol

Integrated Risk Information System (IRIS)

Tricresol ; CASRN 1319 - 77 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Trifluralin

Integrated Risk Information System (IRIS)

Trifluralin ; CASRN 1582 - 09 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Alar

Integrated Risk Information System (IRIS)

Alar ; CASRN 1596 - 84 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Heptachlor

Integrated Risk Information System (IRIS)

Heptachlor ; CASRN 76 - 44 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Hexabromodiphenyl ether

Integrated Risk Information System (IRIS)

Hexabromodiphenyl ether ; CASRN 36483 - 60 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarc

Nitroguanidine

Integrated Risk Information System (IRIS)

Nitroguanidine ; CASRN 556 - 88 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Resmethrin

Integrated Risk Information System (IRIS)

Resmethrin ; CASRN 10453 - 86 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Acrylonitrile

Integrated Risk Information System (IRIS)

Acrylonitrile ; CASRN 107 - 13 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Phosphoric acid

Integrated Risk Information System (IRIS)

Phosphoric acid ; CASRN 7664 - 38 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Pyrene

Integrated Risk Information System (IRIS)

Pyrene ; CASRN 129 - 00 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Captan

Integrated Risk Information System (IRIS)

Captan ; CASRN 133 - 06 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Pydrin

Integrated Risk Information System (IRIS)

Pydrin ; CASRN 51630 - 58 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Arsenic, inorganic

Integrated Risk Information System (IRIS)

Arsenic , inorganic ; CASRN 7440 - 38 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Toxaphene

Integrated Risk Information System (IRIS)

Toxaphene ; CASRN 8001 - 35 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Benzidine

Integrated Risk Information System (IRIS)

Benzidine ; CASRN 92 - 87 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Hexachlorophene

Integrated Risk Information System (IRIS)

Hexachlorophene ; CASRN 70 - 30 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Antimony trioxide

Integrated Risk Information System (IRIS)

Antimony trioxide ; CASRN 1309 - 64 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Thiobencarb

Integrated Risk Information System (IRIS)

Thiobencarb ; CASRN 28249 - 77 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Dacthal

Integrated Risk Information System (IRIS)

Dacthal ; CASRN 1861 - 32 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Dimethyl phthalate

Integrated Risk Information System (IRIS)

Dimethyl phthalate ; CASRN 131 - 11 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Ametryn

Integrated Risk Information System (IRIS)

Ametryn ; CASRN 834 - 12 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

1-Chlorobutane

Integrated Risk Information System (IRIS)

1 - Chlorobutane ; CASRN 109 - 69 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Hydrogen chloride

Integrated Risk Information System (IRIS)

Hydrogen chloride ; CASRN 7647 - 01 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Quinalphos

Integrated Risk Information System (IRIS)

Quinalphos ; CASRN 13593 - 03 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Fonofos

Integrated Risk Information System (IRIS)

Fonofos ; CASRN 944 - 22 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Maleic hydrazide

Integrated Risk Information System (IRIS)

Maleic hydrazide ; CASRN 123 - 33 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

ortho-Anisidine

Integrated Risk Information System (IRIS)

ortho - Anisidine ; CASRN 90 - 04 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Chlorobenzilate

Integrated Risk Information System (IRIS)

Chlorobenzilate ; CASRN 510 - 15 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Nickel carbonyl

Integrated Risk Information System (IRIS)

Nickel carbonyl ; CASRN 13463 - 39 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

o-Dinitrobenzene

Integrated Risk Information System (IRIS)

o - Dinitrobenzene ; CASRN 528 - 29 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Mercury, elemental

Integrated Risk Information System (IRIS)

Mercury , elemental ; CASRN 7439 - 97 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Naled

Integrated Risk Information System (IRIS)

Naled ; CASRN 300 - 76 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Pentachloronitrobenzene (PCNB)

Integrated Risk Information System (IRIS)

Pentachloronitrobenzene ( PCNB ) ; CASRN 82 - 68 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for N

Sodium fluoroacetate

Integrated Risk Information System (IRIS)

Sodium fluoroacetate ; CASRN 62 - 74 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Molinate

Integrated Risk Information System (IRIS)

Molinate ; CASRN 2212 - 67 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Isopropalin

Integrated Risk Information System (IRIS)

Isopropalin ; CASRN 33820 - 53 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Terbutryn

Integrated Risk Information System (IRIS)

Terbutryn ; CASRN 886 - 50 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Savey

Integrated Risk Information System (IRIS)

Savey ; CASRN 78587 - 05 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Fluorene

Integrated Risk Information System (IRIS)

Fluorene ; CASRN 86 - 73 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

t-Butylchloride

Integrated Risk Information System (IRIS)

t - Butylchloride ; CASRN 507 - 20 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Apollo

Integrated Risk Information System (IRIS)

Apollo ; CASRN 74115 - 24 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Pronamide

Integrated Risk Information System (IRIS)

Pronamide ; CASRN 23950 - 58 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Molybdenum

Integrated Risk Information System (IRIS)

Molybdenum ; CASRN 7439 - 98 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

2-Chloroacetophenone

Integrated Risk Information System (IRIS)

2 - Chloroacetophenone ; CASRN 532 - 27 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Diphenamid

Integrated Risk Information System (IRIS)

Diphenamid ; CASRN 957 - 51 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Naphthalene

Integrated Risk Information System (IRIS)

Naphthalene ; CASRN 91 - 20 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Phenanthrene

Integrated Risk Information System (IRIS)

Phenanthrene ; CASRN 85 - 01 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Ammonium sulfamate

Integrated Risk Information System (IRIS)

Ammonium sulfamate ; CASRN 7773 - 06 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Alachlor

Integrated Risk Information System (IRIS)

Alachlor ; CASRN 15972 - 60 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Chlorpyrifos

Integrated Risk Information System (IRIS)

Chlorpyrifos ; CASRN 2921 - 88 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

o-Chlorotoluene

Integrated Risk Information System (IRIS)

o - Chlorotoluene ; CASRN 95 - 49 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Ethylbenzene

Integrated Risk Information System (IRIS)

Ethylbenzene ; CASRN 100 - 41 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

3-Methylphenol

Integrated Risk Information System (IRIS)

3 - Methylphenol ; CASRN 108 - 39 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Metolachlor

Integrated Risk Information System (IRIS)

Metolachlor ; CASRN 51218 - 45 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Furfural

Integrated Risk Information System (IRIS)

Furfural ; CASRN 98 - 01 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Uranium, natural

Integrated Risk Information System (IRIS)

Uranium , natural ; CASRN 7440 - 61 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

Aldicarb sulfone

Integrated Risk Information System (IRIS)

Aldicarb sulfone ; CASRN 1646 - 88 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Londax

Integrated Risk Information System (IRIS)

Londax ; CASRN 83055 - 99 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

2-Methoxyethanol

Integrated Risk Information System (IRIS)

2 - Methoxyethanol ; CASRN 109 - 86 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogeni

N-Nitrosodiphenylamine

Integrated Risk Information System (IRIS)

N - Nitrosodiphenylamine ; CASRN 86 - 30 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Ethephon

Integrated Risk Information System (IRIS)

Ethephon ; CASRN 16672 - 87 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Brominated dibenzofurans

Integrated Risk Information System (IRIS)

Brominated dibenzofurans ; no CASRN Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Acetophenone

Integrated Risk Information System (IRIS)

Acetophenone ; CASRN 98 - 86 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Fluoranthene

Integrated Risk Information System (IRIS)

Fluoranthene ; CASRN 206 - 44 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Oxamyl

Integrated Risk Information System (IRIS)

Oxamyl ; CASRN 23135 - 22 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Warfarin

Integrated Risk Information System (IRIS)

Warfarin ; CASRN 81 - 81 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Propanil

Integrated Risk Information System (IRIS)

Propanil ; CASRN 709 - 98 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Metribuzin

Integrated Risk Information System (IRIS)

Metribuzin ; CASRN 21087 - 64 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Butylate

Integrated Risk Information System (IRIS)

Butylate ; CASRN 2008 - 41 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Demeton

Integrated Risk Information System (IRIS)

Demeton ; CASRN 8065 - 48 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Strontium

Integrated Risk Information System (IRIS)

Strontium ; CASRN 7440 - 24 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

N-Nitrosopyrrolidine

Integrated Risk Information System (IRIS)

N - Nitrosopyrrolidine ; CASRN 930 - 55 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Selenourea

Integrated Risk Information System (IRIS)

Selenourea ; CASRN 630 - 10 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Bromomethane

Integrated Risk Information System (IRIS)

Bromomethane ; CASRN 74 - 83 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Phosgene

Integrated Risk Information System (IRIS)

Phosgene ; CASRN 75 - 44 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Carbosulfan

Integrated Risk Information System (IRIS)

Carbosulfan ; CASRN 55285 - 14 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Nitrapyrin

Integrated Risk Information System (IRIS)

Nitrapyrin ; CASRN 1929 - 82 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Heptachlor epoxide

Integrated Risk Information System (IRIS)

Heptachlor epoxide ; CASRN 1024 - 57 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Iprodione

Integrated Risk Information System (IRIS)

Iprodione ; CASRN 36734 - 19 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Mirex

Integrated Risk Information System (IRIS)

Mirex ; CASRN 2385 - 85 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Metalaxyl

Integrated Risk Information System (IRIS)

Metalaxyl ; CASRN 57837 - 19 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Diflubenzuron

Integrated Risk Information System (IRIS)

Diflubenzuron ; CASRN 35367 - 38 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Methomyl

Integrated Risk Information System (IRIS)

Methomyl ; CASRN 16752 - 77 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Thallium selenite

Integrated Risk Information System (IRIS)

Thallium selenite ; CASRN 12039 - 52 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Triasulfuron

Integrated Risk Information System (IRIS)

Triasulfuron ; CASRN 82097 - 50 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Benzaldehyde

Integrated Risk Information System (IRIS)

Benzaldehyde ; CASRN 100 - 52 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Methyl chlorocarbonate

Integrated Risk Information System (IRIS)

Methyl chlorocarbonate ; CASRN 79 - 22 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinog

Phthalic anhydride

Integrated Risk Information System (IRIS)

Phthalic anhydride ; CASRN 85 - 44 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Arsine

Integrated Risk Information System (IRIS)

Arsine ; CASRN 7784 - 42 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Pentabromodiphenyl ether

Integrated Risk Information System (IRIS)

Pentabromodiphenyl ether ; CASRN 32534 - 81 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncar

Phosmet

Integrated Risk Information System (IRIS)

Phosmet ; CASRN 732 - 11 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Propazine

Integrated Risk Information System (IRIS)

Propazine ; CASRN 139 - 40 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Methoxychlor

Integrated Risk Information System (IRIS)

Methoxychlor ; CASRN 72 - 43 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Dimethylamine

Integrated Risk Information System (IRIS)

Dimethylamine ; CASRN 124 - 40 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Captafol

Integrated Risk Information System (IRIS)

Captafol ; CASRN 2425 - 06 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Express

Integrated Risk Information System (IRIS)

Express ; CASRN 101200 - 48 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Dichlorvos

Integrated Risk Information System (IRIS)

Dichlorvos ; CASRN 62 - 73 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

2-Ethoxyethanol

Integrated Risk Information System (IRIS)

2 - Ethoxyethanol ; CASRN 110 - 80 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Carboxin

Integrated Risk Information System (IRIS)

Carboxin ; CASRN 5234 - 68 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Bromoform

Integrated Risk Information System (IRIS)

Bromoform ; CASRN 75 - 25 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Chlorine cyanide

Integrated Risk Information System (IRIS)

Chlorine cyanide ; CASRN 506 - 77 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Ethion

Integrated Risk Information System (IRIS)

Ethion ; CASRN 563 - 12 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Ammonium acetate

Integrated Risk Information System (IRIS)

Ammonium acetate ; CASRN 631 - 61 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Endrin

Integrated Risk Information System (IRIS)

Endrin ; CASRN 72 - 20 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects ) a

Phosalone

Integrated Risk Information System (IRIS)

Phosalone ; CASRN 2310 - 17 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Tralomethrin

Integrated Risk Information System (IRIS)

Tralomethrin ; CASRN 66841 - 25 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Aldicarb

Integrated Risk Information System (IRIS)

Aldicarb ( CASRN 116 - 06 - 3 ) Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Merphos

Integrated Risk Information System (IRIS)

Merphos ; CASRN 150 - 50 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Glycidaldehyde

Integrated Risk Information System (IRIS)

Glycidaldehyde ; CASRN 765 - 34 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Dicofol

Integrated Risk Information System (IRIS)

Dicofol ; CASRN 115 - 32 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Azobenzene

Integrated Risk Information System (IRIS)

Azobenzene ; CASRN 103 - 33 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Dinoseb

Integrated Risk Information System (IRIS)

Dinoseb ; CASRN 88 - 85 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Propachlor

Integrated Risk Information System (IRIS)

Propachlor ; CASRN 1918 - 16 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Disulfoton

Integrated Risk Information System (IRIS)

Disulfoton ; CASRN 298 - 04 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Ethyleneimine

Integrated Risk Information System (IRIS)

Ethyleneimine ; CASRN 151 - 56 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Sodium diethyldithiocarbamate

Integrated Risk Information System (IRIS)

Sodium diethyldithiocarbamate ; CASRN 148 - 18 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Non

Dieldrin

Integrated Risk Information System (IRIS)

Dieldrin ; CASRN 60 - 57 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

Systhane

Integrated Risk Information System (IRIS)

Systhane ; CASRN 88671 - 89 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Hexazinone

Integrated Risk Information System (IRIS)

Hexazinone ; CASRN 51235 - 04 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Tetrabromodiphenyl ether

Integrated Risk Information System (IRIS)

Tetrabromodiphenyl ether ; CASRN 40088 - 47 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncar

Glyphosate

Integrated Risk Information System (IRIS)

Glyphosate ; CASRN 1071 - 83 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effec

Adiponitrile

Integrated Risk Information System (IRIS)

Adiponitrile ; CASRN 111 - 69 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Ammonium methacrylate

Integrated Risk Information System (IRIS)

Ammonium methacrylate ; CASRN 16325 - 47 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

p-Chloroaniline

Integrated Risk Information System (IRIS)

p - Chloroaniline ; CASRN 106 - 47 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

m-Phenylenediamine

Integrated Risk Information System (IRIS)

m - Phenylenediamine ; CASRN 108 - 45 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Tebuthiuron

Integrated Risk Information System (IRIS)

Tebuthiuron ; CASRN 34014 - 18 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Malathion

Integrated Risk Information System (IRIS)

Malathion ; CASRN 121 - 75 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Picloram

Integrated Risk Information System (IRIS)

Picloram ; CASRN 1918 - 02 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Ethylphthalyl ethylglycolate (EPEG)

Integrated Risk Information System (IRIS)

Ethylphthalyl ethylglycolate ( EPEG ) ; CASRN 84 - 72 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments

Atrazine

Integrated Risk Information System (IRIS)

Atrazine ; CASRN 1912 - 24 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

Prochloraz

Integrated Risk Information System (IRIS)

Prochloraz ; CASRN 67747 - 09 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Copper

Integrated Risk Information System (IRIS)

Copper ; CASRN 7440 - 50 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects )

IRIS Bimonthly Public Meeting (Oct 2014)

EPA Pesticide Factsheets

The meeting was held to obtain input from the scientific community and the public on studies and data that will be used in the assessments of Diisononyl Phthalate (DINP) and Hexavalent Chromium (Cr(VI)) that are under IRIS development.

Inertial Movements of the Iris as the Origin of Postsaccadic Oscillations.

PubMed

Bouzat, S; Freije, M L; Frapiccini, A L; Gasaneo, G

2018-04-27

Recent studies on the human eye indicate that the pupil moves inside the eyeball due to deformations of the iris. Here we show that this phenomenon can be originated by inertial forces undergone by the iris during the rotation of the eyeball. Moreover, these forces affect the iris in such a way that the pupil behaves effectively as a massive particle. To show this, we develop a model based on the Newton equation on the noninertial reference frame of the eyeball. The model allows us to reproduce and interpret several important findings of recent eye-tracking experiments on saccadic movements. In particular, we get correct results for the dependence of the amplitude and period of the postsaccadic oscillations on the saccade size and also for the peak velocity. The model developed may serve as a tool for characterizing eye properties of individuals.

Inertial Movements of the Iris as the Origin of Postsaccadic Oscillations

NASA Astrophysics Data System (ADS)

Bouzat, S.; Freije, M. L.; Frapiccini, A. L.; Gasaneo, G.

2018-04-01

Recent studies on the human eye indicate that the pupil moves inside the eyeball due to deformations of the iris. Here we show that this phenomenon can be originated by inertial forces undergone by the iris during the rotation of the eyeball. Moreover, these forces affect the iris in such a way that the pupil behaves effectively as a massive particle. To show this, we develop a model based on the Newton equation on the noninertial reference frame of the eyeball. The model allows us to reproduce and interpret several important findings of recent eye-tracking experiments on saccadic movements. In particular, we get correct results for the dependence of the amplitude and period of the postsaccadic oscillations on the saccade size and also for the peak velocity. The model developed may serve as a tool for characterizing eye properties of individuals.

1D Self-Assembly and Ice Recrystallization Inhibition Activity of Antifreeze Glycopeptide-Functionalized Perylene Bisimides.

PubMed

Adam, Madeleine K; Jarrett-Wilkins, Charles; Beards, Michael; Staykov, Emiliyan; MacFarlane, Liam R; Bell, Toby D M; Matthews, Jacqueline M; Manners, Ian; Faul, Charl F J; Moens, Pierre D J; Ben, Robert N; Wilkinson, Brendan L

2018-06-04

Antifreeze glycoproteins (AFGPs) are polymeric natural products that have drawn considerable interest in diverse research fields owing to their potent ice recrystallization inhibition (IRI) activity. Self-assembled materials have emerged as a promising class of biomimetic ice growth inhibitor, yet the development of AFGP-based supramolecular materials that emulate the aggregative behavior of AFGPs have not yet been reported. This work reports the first example of the 1D self-assembly and IRI activity of AFGP-functionalized perylene bisimides (AFGP-PBIs). Glycopeptide-functionalized PBIs underwent 1D self-assembly in water and showed modest IRI activity, which could be tuned through substitution of the PBI core. This work presents essential proof-of-principle for the development of novel IRIs as potential supramolecular cryoprotectants and glycoprotein mimics. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Cyberinfrastructure at IRIS: Challenges and Solutions Providing Integrated Data Access to EarthScope and Other Earth Science Data

NASA Astrophysics Data System (ADS)

Ahern, T. K.; Barga, R.; Casey, R.; Kamb, L.; Parastatidis, S.; Stromme, S.; Weertman, B. T.

2008-12-01

While mature methods of accessing seismic data from the IRIS DMC have existed for decades, the demands for improved interdisciplinary data integration call for new approaches. Talented software teams at the IRIS DMC, UNAVCO and the ICDP in Germany, have been developing web services for all EarthScope data including data from USArray, PBO and SAFOD. These web services are based upon SOAP and WSDL. The EarthScope Data Portal was the first external system to access data holdings from the IRIS DMC using Web Services. EarthScope will also draw more heavily upon products to aid in cross-disciplinary data reuse. A Product Management System called SPADE allows archive of and access to heterogeneous data products, presented as XML documents, at the IRIS DMC. Searchable metadata are extracted from the XML and enable powerful searches for products from EarthScope and other data sources. IRIS is teaming with the External Research Group at Microsoft Research to leverage a powerful Scientific Workflow Engine (Trident) and interact with the web services developed at centers such as IRIS to enable access to data services as well as computational services. We believe that this approach will allow web- based control of workflows and the invocation of computational services that transform data. This capability will greatly improve access to data across scientific disciplines. This presentation will review some of the traditional access tools as well as many of the newer approaches that use web services, scientific workflow to improve interdisciplinary data access.

Anterior Segment Optical Coherence Tomography Angiography for Identification of Iris Vasculature and Staging of Iris Neovascularization: A Pilot Study.

PubMed

Roberts, Philipp K; Goldstein, Debra A; Fawzi, Amani A

2017-08-01

Purpose/Aim of the study: To assess the ability of optical coherence tomographic angiography (OCTA) to visualize the normal iris vasculature as well as neovascularization of the iris (NVI). Study participants with healthy eyes, patients at risk of NVI development and patients with active or regressed NVI were consecutively included in this cross-sectional observational study. Imaging was performed using a commercially available OCTA system (RTVue- XR Avanti, Optovue Inc., Fremont, CA, USA). Abnormal iris vessels were graded on OCTA according to a modified clinical staging system and compared to slitlamp and gonioscopic findings. Fifty eyes of 26 study participants (16 healthy eyes, 19 eyes at risk, 15 eyes with different stages of NVI) were imaged using OCTA. In 11 out of 16 healthy eyes (69%) with light or moderately dark iris pigmentation, we observed physiological, radially aligned iris vasculature on OCTA imaging, which could not be visualized in five eyes (31%) with darkly pigmented irides. One eye in the "eyes at risk" group was diagnosed with NVI based on OCTA, which was not observed clinically. Fifteen eyes with clinically active or regressed NVI were imaged. Different stages of NVI could be differentiated by OCTA, corresponding well to an established clinical grading system. Four eyes showed regressed NVI by OCTA, not seen clinically, and were graded as a newly defined stage 4. This pilot clinical study showed that OCTA for imaging of the iris vasculature in health and disease is highly dependent on iris pigmentation. Fine, clinically invisible iris vessels can be visualized by OCTA in the very early stages as well as in the regressed stage of NVI.

Anterior Segment Optical Coherence Tomography Angiography for Identification of Iris Vasculature and Staging of Iris Neovascularization: A Pilot Study

PubMed Central

Roberts, Philipp K.; Goldstein, Debra A.; Fawzi, Amani A.

2017-01-01

Purpose/Aim of the study To assess the ability of optical coherence tomographic angiography (OCTA) to visualize the normal iris vasculature as well as neovascularization of the iris (NVI). Materials and Methods Study participants with healthy eyes, patients at risk of NVI development and patients with active or regressed NVI were consecutively included in this cross-sectional observational study. Imaging was performed using a commercially available OCTA system (RTVue- XR Avanti, Optovue Inc., Fremont, CA, USA). Abnormal iris vessels were graded on OCTA according to a modified clinical staging system and compared to slitlamp and gonioscopic findings. Results Fifty eyes of 26 study participants (16 healthy eyes, 19 eyes at risk, 15 eyes with different stages of NVI) were imaged using OCTA. In 11 out of 16 healthy eyes (69%) with light or moderately dark iris pigmentation, we observed physiological, radially aligned iris vasculature on OCTA imaging, which could not be visualized in five eyes (31%) with darkly pigmented irides. One eye in the “eyes at risk” group was diagnosed with NVI based on OCTA, which was not observed clinically. Fifteen eyes with clinically active or regressed NVI were imaged. Different stages of NVI could be differentiated by OCTA, corresponding well to an established clinical grading system. Four eyes showed regressed NVI by OCTA, not seen clinically, and were graded as a newly defined stage 4. Conclusions This pilot clinical study showed that OCTA for imaging of the iris vasculature in health and disease is highly dependent on iris pigmentation. Fine, clinically invisible iris vessels can be visualized by OCTA in the very early stages as well as in the regressed stage of NVI. PMID:28441067

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.

PubMed

Bogan, Danielle; Meile, Lucio; El Bastawisy, Ahmed; Yousef, Hend F; Zekri, Abdel-Rahman N; Bahnassy, Abeer A; ElShamy, Wael M

2017-05-12

Breast cancer is the most globally diagnosed female cancer, with the triple negative breast cancer (TNBC) being the most aggressive subtype of the disease. In this study we aimed at comparing the effect of BRCA1-IRIS overexpression on the clinico-pathological characteristics in breast cancer patients with TNBC or non-TNBC in the largest comprehensive cancer center in Egypt. To reach this goal, we conducted an observational study at the National Cancer Institute (NCI), Cairo University (Cairo, Egypt). The data on all diagnosed breast cancer patients, between 2009 and 2012, were reviewed. BRCA1-IRIS expression measured using real time RT/PCR in these patients' tumor samples was correlated to tumor characteristics, such as to clinico-pathological features, therapeutic responses, and survival outcomes. 96 patients were enrolled and of these 45% were TNBC, and 55% were of other subtypes (hereafter, non-TNBC). All patients presented with invasive ductal carcinomas. No significant difference was observed for risk factors, such as age and menopausal status between the TNBC and the non-TNBC groups except after BRCA1-IRIS expression was factored in. The majority of the tumors in both groups were ≤5 cm at surgery (p = 0.013). However, in the TNBC group, ≤5 cm tumors were BRCA1-IRIS-overexpressing, whereas in the non-TNBC group they were BRCA1-IRIS-negative (p = 0.00007). Most of the TNBC patients diagnosed with grade 1 or 2 were BRCA1-IRIS-overexpressing, whereas non-TNBCs were IRIS-negative (p = 0.00035). No statistical significance was measured in patients diagnosed with grade 3 tumors. Statistically significant difference between TNBCs and non-TNBCs and tumor stage with regard to BRCA1-IRIS-overexpression was observed. Presence of axillary lymph node metastases was positively associated with BRCA1-IRIS overexpression in TNBC group, and with BRCA1-IRIS-negative status in the non-TNBC group (p = 0.00009). Relapse after chemotherapy (p < 0.00001), and local recurrence/distant metastasis after surgery (p = 0.0028) were more pronounced in TNBC patients with BRCA1-IRIS-overexpressing tumors compared to non-TNBC patients. Finally, decreased disease-free survival in TNBC/BRCA1-IRIS-overexpressing patients compared to TNBC/BRCA1-IRIS-negative patients, and decreased overall survival in TNBC as well as non-TNBC patients was driven by BRCA1-IRIS overexpression. TNBC/BRCA1-IRIS-overexpressing tumors are more aggressive than TNBC/BRCA1-IRIS-negative or non-TNBC/BRCA1-IRIS-overexpressing or both negative tumors. Further studies are warranted to define whether BRCA1-IRIS drives the early TNBC lesions growth and dissemination and whether it could be used as a diagnostic biomarker and/or therapeutic target for these lesions at an early stage setting.

IRIS TOXICOLOGICAL REVIEW AND SUMMARY ...

EPA Pesticide Factsheets

Trichloroacetic acid is a crystalline solid with sharp, pungent odor. It is used as a soil sterilizer; and as a laboratory intermediate or reagent in the synthesis of a variety of medicinal products and organic chemicals. Trichloroacetic acid is also used industrially as an etching and pickling agent for the surface treatment of metals and as a solvent in the plastics industry. Trichloroacetic acid can be formed as a combustion byproduct of organic compounds in the presence of chlorine. It is also formed as a disinfection byproduct during water chlorination. The existing IRIS entry was added to the IRIS data base between 1994 and 1996. No RfD was developed. The IRIS program is updating the IRIS assessment for Trichloroacetic Acid. This update will incorporate health effects information published since the last assessment was prepared as well as new risk assessment methods. The IRIS assessment for Trichloroacetic Acid will consist of a Toxicological Review and IRIS Summary. The Toxicological Review is a critical review of the physicochemical and toxicokinetic properties of the chemical and its toxicity in humans and experimental systems. The assessment will present reference value for noncancer effects of Trichloroacetic Acid (RfD) and a cancer assessment. The Toxicological Review and IRIS Summary will be subject to internal peer consultation, Agency review and external scientific peer review. The final products will constitute the Agency's opinion on the

Vascular tumors of the iris in 45 patients: the 2009 Helen Keller Lecture.

PubMed

Shields, Jerry A; Bianciotto, Carlos; Kligman, Brad E; Shields, Carol L

2010-09-01

To report on a series of vascular tumors of the iris. Noncomparative case series. A retrospective medical record review of all patients with an iris vascular tumor was performed to identify the clinical features and develop a simple classification of these lesions. Included were demographics, clinical features, systemic associations, complications, management, and histopathology. There were 54 eyes in 45 patients with an iris vascular tumor. These were categorized as racemose hemangioma (41 eyes: 29 simple and 12 complex), cavernous hemangioma (3 eyes: 2 localized and 1 systemic), capillary hemangioma (1 eye, localized), varix (3 eyes, localized), and microhemangiomatosis (6 eyes, localized). The hemangiomas occurred in adults at a median age of 55 years, whereas capillary hemangioma occurred in infancy and cavernous hemangioma with systemic involvement occurred in a child. Of the 41 eyes with iris racemose hemangioma, none showed systemic involvement. Of all 54 eyes, transient hyphema was the main complication, found at some point in 30% or more of each affected eye except for iris capillary and racemose hemangioma. Surgical resection was necessary in 1 cavernous hemangioma and 1 varix. The remainder were managed with observation. There are now well-documented examples of iris racemose hemangioma, cavernous hemangioma, capillary hemangioma, varix, and microhemangiomatosis. Transient hyphema is the main complication. Observation is usually advised. Most are solitary lesions confined to the iris and some (cavernous hemangioma and microhemangiomatosis) can have important systemic associations.

Lack of Radiation Maculopathy After Palladium-103 Plaque Radiotherapy for Iris Melanoma

DOE Office of Scientific and Technical Information (OSTI.GOV)

Yousef, Yacoub A.; Finger, Paul T., E-mail: pfinger@eyecancer.com

2012-07-15

Purpose: To report on the risk of radiation maculopathy for iris and iridociliary melanomas treated by {sup 103}Pd plaque radiotherapy. Methods and Materials: This is a retrospective clinical case series of 30 eyes in 30 patients with melanomas limited to the iris or invading the ciliary body. The main outcome measures included demographic information, laterality, tumor size, location, visual acuity, radiation dose, local control, retinal evaluation, and duration of follow-up. Results: Thirty patients were followed for a median 36 months (range, 12-90 months). Sixteen of 30 tumors (53%) were pure iris melanomas, and 14 (47%) were primary iris melanomas extendingmore » into the ciliary body. Radiation dosimetry showed that the median tumor apex dose was 85 Gy (range, 75-100 Gy), lens dose 43.5 Gy (range, 17.8-60 Gy), fovea dose 1.8 Gy (range, 1.3-5 Gy), and central optic disc dose 1.7 Gy (range, 1.3-4.7 Gy). Cataracts developed in 20 of the 28 phakic eyes (71.4%). No patient in this series developed radiation maculopathy or radiation optic neuropathy. Last best-corrected visual acuity was {>=}20/25 in 28 patients (93%) at a median 36 months' follow-up. Conclusion: Though visual acuities were transiently affected by radiation cataract, no radiation maculopathy or optic neuropathy has been noted after {sup 103}Pd treatment of iris and iridociliary melanomas.« less

1,3-Dichlorobenzene

Integrated Risk Information System (IRIS)

1,3 - Dichlorobenzene ; CASRN 541 - 73 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinog

Fluorine (soluble fluoride)

Integrated Risk Information System (IRIS)

Fluorine ( soluble fluoride ) ; CASRN 7782 - 41 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for No

Propylene oxide

Integrated Risk Information System (IRIS)

Propylene oxide ; CASRN 75 - 56 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Polychlorinated biphenyls (PCBs)

Integrated Risk Information System (IRIS)

Polychlorinated biphenyls ( PCBs ) ; CASRN 1336 - 36 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments f

Bisphenol A.

Integrated Risk Information System (IRIS)

Bisphenol A ; CASRN 80 - 05 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Isobutyl alcohol

Integrated Risk Information System (IRIS)

Isobutyl alcohol ; CASRN 78 - 83 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

alpha-Hexachlorocyclohexane (alpha-HCH)

Integrated Risk Information System (IRIS)

alpha - Hexachlorocyclohexane ( alpha - HCH ) ; CASRN 319 - 84 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Ass

Vinyl acetate

Integrated Risk Information System (IRIS)

Vinyl acetate ; CASRN 108 - 05 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

Formic acid

Integrated Risk Information System (IRIS)

Formic acid ; CASRN 64 - 18 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Allyl alcohol

Integrated Risk Information System (IRIS)

Allyl alcohol ; CASRN 107 - 18 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

N-N-Dimethylaniline

Integrated Risk Information System (IRIS)

N - N - Dimethylaniline ; CASRN 121 - 69 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

1,2-Diphenylhydrazine

Integrated Risk Information System (IRIS)

1,2 - Diphenylhydrazine ; CASRN 122 - 66 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Refractory ceramic fibers

Integrated Risk Information System (IRIS)

Refractory ceramic fibers ; CASRN Not found Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcino

Tetraethyl lead

Integrated Risk Information System (IRIS)

Tetraethyl lead ; CASRN 78 - 00 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Dimethyl terephthalate (DMT)

Integrated Risk Information System (IRIS)

Dimethyl terephthalate ( DMT ) ; CASRN 120 - 61 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for No

Dibutyl phthalate (DBP)

Integrated Risk Information System (IRIS)

Dibutyl phthalate ; CASRN 84 - 74 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic

Boron and Compounds

Integrated Risk Information System (IRIS)

Boron and Compounds ; CASRN 7440 - 42 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Zinc and Compounds

Integrated Risk Information System (IRIS)

Zinc and Compounds ; CASRN 7440 - 66 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Chloral hydrate

Integrated Risk Information System (IRIS)

Chloral hydrate ; CASRN 302 - 17 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

3,4-Dimethylphenol

Integrated Risk Information System (IRIS)

3,4 - Dimethylphenol ; CASRN 95 - 65 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Methyl acrylate

Integrated Risk Information System (IRIS)

Methyl acrylate ; CASRN 96 - 33 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Zinc cyanide

Integrated Risk Information System (IRIS)

Zinc cyanide ; CASRN 557 - 21 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Methyl chloride

Integrated Risk Information System (IRIS)

Methyl chloride ; CASRN 74 - 87 - 3 ( 07 / 17 / 2001 ) Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for

Benzo[k]fluoranthene

Integrated Risk Information System (IRIS)

Benzo [ k ] fluoranthene ; CASRN 207 - 08 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarci

Acetyl chloride

Integrated Risk Information System (IRIS)

Acetyl chloride ; CASRN 75 - 36 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Diethylene glycol dinitrate (DEGDN)

Integrated Risk Information System (IRIS)

Diethylene glycol dinitrate ( DEGDN ) ; CASRN 693 - 21 - 0 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments

1,1-Difluoroethane

Integrated Risk Information System (IRIS)

1,1 - Difluoroethane ; CASRN 75 - 37 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogen

Nitric oxide

Integrated Risk Information System (IRIS)

Nitric oxide ; CASRN 10102 - 43 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

d-Limonene

Integrated Risk Information System (IRIS)

d - Limonene ; CASRN 5989 - 27 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

p,p\\'-Dichlorodiphenyltrichloroethane (DDT)

Integrated Risk Information System (IRIS)

p , p ' - Dichlorodiphenyltrichloroethane ( DDT ) ; CASRN 50 - 29 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard

Ethylene glycol

Integrated Risk Information System (IRIS)

Ethylene glycol ; CASRN 107 - 21 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Ethylene thiourea (ETU)

Integrated Risk Information System (IRIS)

Ethylene thiourea ( ETU ) ; CASRN 96 - 45 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarci

Ethyl ether

Integrated Risk Information System (IRIS)

Ethyl ether ; CASRN 60 - 29 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Methylmercury (MeHg)

Integrated Risk Information System (IRIS)

Methylmercury ( MeHg ) ; CASRN 22967 - 92 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarci

Ethyl acetate

Integrated Risk Information System (IRIS)

Ethyl acetate ; CASRN 141 - 78 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Eff

2-Hexanone

Integrated Risk Information System (IRIS)

2 - Hexanone ; CASRN 591 - 78 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

Sodium azide

Integrated Risk Information System (IRIS)

Sodium azide ; CASRN 26628 - 22 - 8 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Methyl iodide

Integrated Risk Information System (IRIS)

Methyl iodide ; CASRN 74 - 88 - 4 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effe

n-Hexane

Integrated Risk Information System (IRIS)

n - Hexane ; CASRN 110 - 54 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effect

Diethyl sulfate

Integrated Risk Information System (IRIS)

Diethyl sulfate ; CASRN 64 - 67 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Coke oven emissions

Integrated Risk Information System (IRIS)

Coke oven emissions ; CASRN NA Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Effects

epsilon-Hexachlorocyclohexane (epsilon-HC)

Integrated Risk Information System (IRIS)

epsilon - Hexachlorocyclohexane ( epsilon - HC ) ; CASRN 6108 - 10 - 7 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard

2,4-Dinitrotoluene

Integrated Risk Information System (IRIS)

2,4 - Dinitrotoluene ; CASRN 121 - 14 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

2,4-Dichlorophenol

Integrated Risk Information System (IRIS)

2,4 - Dichlorophenol ; CASRN 120 - 83 - 2 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinoge

Copper cyanide

Integrated Risk Information System (IRIS)

Copper cyanide ; CASRN 544 - 92 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Barium cyanide

Integrated Risk Information System (IRIS)

Barium cyanide ; CASRN 542 - 62 - 1 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

Propylene glycol

Integrated Risk Information System (IRIS)

Propylene glycol ; CASRN 57 - 55 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic E

Diethyl-p-nitrophenylphosphate

Integrated Risk Information System (IRIS)

Diethyl - p - nitrophenylphosphate ; CASRN 311 - 45 - 5 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments fo

N-Nitroso-N-methylethylamine

Integrated Risk Information System (IRIS)

N - Nitroso - N - methylethylamine ; CASRN 10595 - 95 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments

Aroclor 1248

Integrated Risk Information System (IRIS)

Aroclor 1248 ; CASRN 12672 - 29 - 6 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcinogenic Ef

p-Bromodiphenyl ether

Integrated Risk Information System (IRIS)

p - Bromodiphenyl ether ; CASRN 101 - 55 - 3 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarcin

Tributyltin oxide (TBTO)

Integrated Risk Information System (IRIS)

Tributyltin oxide ( TBTO ) ; CASRN 56 - 35 - 9 Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data , as outlined in the IRIS assessment development process . Sections I ( Health Hazard Assessments for Noncarc